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Chapter 1 
Introduction  
1.1 The nucleosome and epigenetics 
       Epigenetics describes the heritable phenotypic changes in an organism that do not arise 
from changes in the DNA base sequence. DNA is the genetic bank house in the cell, storing an 
immense amount of genetic instruction that allows cells to maintain many biological functions. 
The patterns of genetic inheritance are, therefore, dependent on the information contained in 
DNA, as well as any epigenetic marks. 
       The human genome contains three billion base pairs, which encode approximately 30,000 
to 40,000 genes. To allow for efficient storage of this enormous size in a cell, approximately 146 
base pairs of DNA are wrapped around an octameric structure consisting of two copies each of 
the histone proteins H2A, H2B, H3 & H4 to form the nucleosome [1]. The nucleosome therefore 
is the simplest unit of DNA storage in a cell. Linker histones (H1) associating with approximately 
10-60bp of DNA further package the nucleosomal structure into chromatin fibers (Figure 1.1). 
Chromatin fibers further condense into chromosomes. This nucleoprotein structure consisting of 
DNA, histone proteins and the linker histones limit the accessibility of DNA. 
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       A high resolution crystal structure (2.8 Å) of the nucleosome was reported by Luger et al. in 
1997. The nucleosomal structure has a disc-like shape, consisting of 1.65 turns of left-handed 
superhelical DNA with 145 DNA base pairs wound around a core nucleosome structure (Figure 
1.2).  This structure revealed that, whereas the C-terminal regions of the histone proteins bind to 
DNA and form the nucleosome core, the N-terminal regions are unstructured and are not 
involved in formation or stability of the nucleosome core but are critical for chromatin 
condensation. Further, the N-terminal tails are rich in basic amino acids. Subsequent studies 
later showed that histones are subject to a number of covalent post-translational modifications 
[2]. 
 
 
Figure 1.1: Duplex DNA is assembled into chromatin fibers. DNA is coiled around histone 
proteins forming the nucleosome. Consecutive nucleosomes are linked via linker histones (H1) 
and short pieces of DNA which further condense into approximately 30 nM chromatin fibers. 
More compacting of chromatin fibers forms the chromatids, which are paired and stored in the 
cell as the genetic material. Reproduced with permission from FEBS Letters, 579 (2005) 895-
898. 
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       To maintain proper functioning in a tissue specific manner, cells have to express gene 
products on demand. The central dogma of molecular biology dictates that DNA can act as a 
template to make a replica DNA daughter molecule or RNA transcript. RNA biosynthesized this 
way is typically further translated into proteins by the ribosome. In addition, for replication, the 
DNA daughter molecule is transferred to a new cell, allowing passage and continuity of genetic 
information. In addition to replication and transcription, gene recombination, repair, and mitotic 
condensation involve chromosomally bound DNA. The question arises: How does 
chromosomally bound DNA become available for any of these processes to occur? Cells have 
to modulate chromatin structure in order to allow for the accurate execution of these processes 
for proper cell functioning. Remodeling of chromatin structure involves a variety of mechanisms. 
1.2 Epigenetics: Histone modifications, chromatic remodeling and DNA marks 
       Post-translational modifications on histones modify the nucleosomal physical structure for 
DNA accessibility. Covalent modifications on the DNA and N-terminal histone tails are central to 
Figure 1.2: Crystal structure of a nucleosome. The duplex DNA (grey) is wrapped around an 
octamer of histone proteins (blue: H3; green: H4; yellow: H2A; and red: H2B). N-terminal lysine-
rich tails on histones are shown by the red arrows (Luger et al Nature 1997 389, 251-260). 
Reproduced with permission from FEBS Let., 579 (2005) 895-898. 
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epigenetic gene regulation. In contrast to the DNA, which is mainly methylated on cystosine 
bases, histone modifications are varied [3, 4]. Key modifications include phosphorylation, 
acetylation methylation, ubuquitination, sumoylation, citrulination and ribosylation [3]. Lysine and 
arginine residues can be mono-, di- or trimethylated; all of which add complexity to histone 
modification patterns.  Combinations of these histone modifications can give rise to a specific 
histone code that dictates the transcriptional status of associated genes [3]. For instance 
combinations of acetylations of H4 K8 and H3 K14, together with phosphorylation of S10 on H3, 
gives rise actively transcribed genes [3]. Besides histone modifications, other epigenetic marks 
involve modifications on the DNA itself, chromatin remodeling and non-coding RNAs [5]. ATP-
dependent chromatin remodeling complexes such as the SWI/SNF (SWItch/Sucrose 
NonFermantable), ISWI (imitation switch) and CHD (chromodomain helicase DNA-binding) 
families of remodelers, are recruited by some histone modifications and eject or move 
nucleosomes allowing DNA access [6]. Importantly, a link between histone modifications and 
DNA methylation has been reported. Specifically, DNA methylation on CpG islands leads to 
transcriptional repression, which is attributed to the recruitment of histone modifiers to promoter 
regions by the methyl- CpG-binding protein 2, MeCP2 [4]. 
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1.3 Histone acetylation and deacetylation 
        Histone acetylation is the most abundant and well studied post-translational modification 
on histones. Two classes of enzymes, histone acetyl transferase (HAT) and histone 
deacetylases (HDAC), mediate the balance between the acetylated and deacetylated states. 
Acetylation has a prominent role in disease states and several small molecules have been 
created that target both histone enzymes.   
        HATs use the cofactor acetyl-coenzyme A to transfer an acetyl-group to the ε-amino group 
of specific lysine residues on histone proteins (Figure 1.4). The removal of the acetyl group is 
catalyzed by HDACs (Figure 1.4).  Acetylation neutralizes the positive charge on the DNA 
backbone to loosely bind to the nucleosomal structure, which results in the open chromatin form 
Figure 1.3: Common histone modifications [3]. Schematic representing the nucleosome core 
with common post-translantional histone modifications, including: acetyl lysine (acK), methyl- 
arginine (meR), methyl lysine (meK), phosphoserine (PS), and ubiquitinated lysine (uK). Post-
translational modifications are represented by colored shapes (legend in bottom left corner). 
Reproduced with permission from Curr. Bio., 2004, 14 (14), 546-51. 
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that is generally associated with actively transcribed genes in euchromatin. Removal of the 
acetyl group by HDACs results in positively charged lysine residues capable of ionic bonding 
with the back to the negatively charged phosphates on DNA. Deacetylated histones bind tightly 
to DNA, making DNA inaccessible to transcription factors and promoting the heterochromatin 
form (Figure 1.5). 
 
 
 
 
 
 
 
Scheme 1.1: Acetylation and deacetylation of the ε-amino group on histone proteins. 
Histone acetyl transferase (HAT) enzymes catalyze the transfer of an acetyl group from the co-
factor acetyl-CoA to lysine residues resulting in a neutral acetyl-lysine. The removal of the acetyl 
group is catalyzed by histone deacetylases (HDAC). Deacetylation results in a cationic lysine 
residue capable of forming ionic interaction with the anionic phosphate backbone on the DNA.  
Acetylation and deacetylation are reversible processes and the key enzymes involved are HATs 
and HDACs. 
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1.4: Histone deacetylases: Classes, structure and mechanism 
1.4.1: Classes of HDAC proteins 
        Eighteen human HDAC proteins are known to date; these are classified into four main 
classes on the basis of size, enzymatic mechanism and sequence homology to yeast proteins. 
Class I HDAC proteins are relatively small, ranging from 49-55 kDa and are homologous to the 
yeast Rpd3 (Reduced potassium dependence 3). Class I includes HDAC1, HDAC2, HDAC3 and 
HDAC8 (Figure 1.5) [7] [8] [9]. The class I HDAC proteins have a metal dependent mechanism, 
which will be discussed in detail in section 1.4.2. The class I HDAC proteins are mainly nuclear 
and are ubiquitously expressed in many cell types, which is in agreement with their role in cell 
cycle regulation in various tissues [7] [10] [11]. 
Figure 1.4: Effect of acetylation and deacetylation of nucleosome on gene transcription. 
(A). Acetylation of histones by histone acetyltransfarases (HAT) makes DNA accessible to 
transcription factors and gene transcription is on (B). Removal of the acetyl group makes DNA 
inaccessible to transcription factors (A) and gene transcription is off. (Picture credit Dr. Pflum) 
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       HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 and HDAC10 belong to the class II subfamily 
and have sequence homology to the yeast HdaI (Histone deacetylase 1) protein and are much 
bigger in size (80-131 kDa) than class I [12-15]. Unlike the other class II isoforms, HDAC6 has 
two active sites on its N-terminal and C-terminus regions, which can be attributed to an in-shift 
gene duplication event [12]. Further, the N-terminus active site is dispensable in HDAC6.  On 
the other hand, HDAC9 and HDAC10 have two splice variants, which possess deacetylase 
activities at comparable levels [15]. The rest of the class II isoforms, HDAC4, HDAC5 and 
HDAC7, have a single active site on their C-terminal domains. In contrast to the class I HDACs, 
which are mainly nuclear and ubiquitously expressed in several cell types, the class II HDACs 
can shuttle from the nucleus to the cytoplasm in response to a specific cell signal, for instance 
to participate in metabolic events [16]. 
Figure 1.5: Summary in length of HDAC classes. Class I HDACs 1-3 and 8 range from 377-
448 amino acids. Class II HDACs: 4-7and 9-10 have 669 to 1122 amino acids.  The class IV 
HDAC11 is 347 amino acids long.  Bars depict the length of the protein. The catalytic domains 
are shown in blue. Black depicts a nuclear localization domain, N, N-terminus, C, and C-
terminus.  
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        The class IV deacetylase, HDAC11, is a 39 kDa protein and is the only class IV member. 
Similar to class I HDACs, HDAC11 has a single active site and is mainly nuclear, but it is 
thought to have diverged in evolution much earlier from the other HDAC proteins [17]. Despite 
these similarities, HDAC11 is expressed in a tissue specific manner with higher levels seen in 
the brain, heart, skeletal muscle and kidneys, suggesting a tissue specific function [17].  
       Class III HDAC proteins are the sirtuins and are homologous to the yeast Sir2 (Silent 
information regulator) proteins and include Sirt1, 2, 3, 4, 5, 6 and 7. Whereas class I, II and IV 
display a similar metal-dependent enzymatic mechanism, class III HDACs require NAD+ for 
catalysis. In this dissertation the sirtuins will not be further discussed because they have a 
different enzymatic mechanism distinct from the other classes and are insensitive to the HDAC 
inhibitors of interest in the Pflum lab. 
       Due to the similarities in catalytic mechanisms among classes I, II and IV HDACs, most 
HDAC inhibitors (HDACi) display pan inhibition towards these enzymes with only a few being 
selective [18, 19]. This topic will be discussed in details in Section 1.6. Additionally, whereas 
class I and II HDACs bind to the mSin3A, RbAp48, N-CoR co-repressors in vivo, HDAC11 does 
not associate with these complexes, suggesting that HDAC11 is distinct from the rest of the 
metal-dependent HDAC proteins [17]. Importantly, the function(s) of the metal-dependent 
HDACs is poorly understood, a current problem in cancer treatment, as will be discussed in 
section 1.5. 
1.4.2: HDAC structure and catalytic mechanism 
       As discussed in section 1.4.1, Classes I, II and IV HDAC proteins have a similar metal-
dependent catalytic mechanism. The crystal structures of a histone deacetylase like protein 
(HDLP) from a thermophilic bacterium Aquifex aeolicus, which displays 35.2% sequence 
homology to HDAC1, has been used as a model to study class I HDAC proteins. The 
10 
 
 
crystallographic structure of HDLP resolved at 2.1 Å in complex with the HDAC inhibitors 
suberoylanilide hydroxamic acid (SAHA, Zolinza) and Trichostatin A (TSA), was reported in 
1999 (Figure 1.6) [20]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
       The HDLP structure revealed that the active site contains a hydrophobic, 11 Å channel that 
interacts with the long hydrophobic linker chain in TSA and SAHA or in acetylated HDAC 
substrates (Figure 1.7). The aromatic phenyl group of TSA and SAHA are located towards the 
solvent exposed region. At the bottom part of the 11 Å channel is a catalytic metal ion that 
interacts with the hydroxamic groups of SAHA and TSA (Figure 1.7). The function of the 14 Å 
channel is unknown. Several biochemical and computational studies have postulated that the 14 
Å channel has two main functions: serving as the exit path for the acetate by-product of the 
Figure 1.6: Crystal structure of the HDAC-like bacterial homolog (HDLP) in complex with 
the HDAC inhibitor SAHA [20]. The phenyl capping group of SAHA projects towards the 
solvent exposed region. The hydrophobic linker chain of SAHA is accommodated in the 11 Å 
channel (also known as the enzyme pocket). The hydroxamic metal binding group of SAHA is at 
the bottom of this channel. The 14 Å channel is located on the other side of the catalytic zinc 
metal ion. Reproduced with permission from Nat., 1999, 401 (6749), 188-93. 
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deacetylation reaction and a shuttling channel for the catalytic water needed in the active site 
(Figure 1.8) [20-22].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: A schematic representation of Trichostatin A (TSA) in the active site of 
HDLP [20]. TSA is in black and the protein is in red. HDLP residues are labeled in red with 
their counterparts in HDAC1 indicated in black. Thatched semi-circles indicate van der Waals 
contacts between hydrophobic protein residues and TSA. Hydrogen bonds are shown as 
green dashed lines. Reproduced with permission from Nat., 1999, 401 (6749), 188-93. 
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       The HDLP structure has been widely used for rational HDAC inhibitor design because the 
amino acids in the catalytic domains of HDLP and most metal-dependent HDACs are similar 
and highly conserved. From this crystallographic data, a plausible mechanism for metal-
dependent HDAC proteins was deduced (section 1.4.3, Scheme 2) [20]. In addition to HDLP, 
the crystal structures for HDAC2, HDAC3, HDAC4, HDAC7 and HDAC8 have been solved [23-
26]. The class II HDACs 4 and 7 gave insights into the active sites of class II deacetylases. 
HDAC4 is a tetramer unlike monomeric HDAC7, which has a structure very similar to HDLP [23, 
24]. The focus of this project is the class I HDAC isoform HDAC1. The crystal structure of the 
class I isoform HDAC8 will be discussed further; the class I isoform HDAC2 structure is not 
thoroughly detailed [27]. 
       The HDAC8 structure is quite distinct from the HDLP structure. It has a dimeric structure 
where the monomers are identical and each binds one Zn2+ and two K+ ions [25]. Similar to the 
HDLP structure, the Zn2+ metal ion in the HDAC8 active site coordinates to the hydroxamic acid 
part of the inhibitors. The K+ ions are thought to influence the deacetylation reaction of HDAC8. 
Specifically, one K+ is located closer to and coordinates with the Zn2+ binding amino acids and is 
Figure 1.8:  Picture of the internal cavity after deacetylation [21]. (A) After deacetylation, the 
lysine chain leaves the 11 Å channel while the byproduct, acetate, passes through the 14 Å 
channel (see arrows). (B) After escape of acetate, the catalytic center accepts water through the 
14 Å channel and acetylated lysine via the 11 Å channel for the next cycle of deacetylation. 
Reprinted with permission from the J. Med. Chem., 2004, 47 (13), 3409-17. 
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therefore likely to influence  the correct orientation and properties of bound residues involved in 
catalysis (Figure 1.9) [25]. Interestingly, the capping groups of the two inhibitor molecules could 
facilitate dimer formation by stacking interactions as well as interactions with nearby residues in 
HDAC8. Similar to HDLP, the 14 Å channel is hypothesized to be involved in acetate release 
[20, 25]. 
 
 
 
 
 
 
 
 
 
 
 
1.4.3: HDAC reaction mechanism 
      From the HDLP crystal structure, a plausible deacetylation mechanism for the metal 
dependent HDACs was proposed (Scheme 1.2). 
 
Figure 1.9: Ribbon diagram of the dimeric structure of HDAC8 shown in yellow (monomer 
A) and indigo (monomer B) colors [25]. The bound inhibitors in the two active sites are shown 
as sticks packed head to tail. Red=oxygen; blue=nitrogen; orange=sulfur. Carbon is shown in 
indigo (molecule A) and yellow (molecule B). Violet spheres, Zn2+ ions; red spheres, K+ ions. 
Reprinted with permission from Proc. Natl. Acad. Sci. U S A., 2004, 101 (42), 15064-9. 
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Scheme 1.2: Proposed chemical mechanism for class I, II and IV HDACs [20]. HDLP-active 
site residues and their proposed HDAC1 counterparts (in parenthesis) are labeled. Reproduced 
with permission from Nat.,1999, 401 (6749), 188-93. 
 
      The deacetylation reaction involves catalytic His and Asp residues acting as general 
acid/base pairs. A catalytic metal ion (can be Zn2+, Co2+ or Fe2+), which coordinates to the Asp, 
the two His residues and a nearby tyrosine residue, form hydrogen bonds to the carbonyl 
oxygen making the carbonyl carbon a better electrophile. Water in the active site is activated by 
the two histidine residues to attack the carbonyl carbon. The resulting tetrahedral intermediate is 
stabilized by the metal ion and the Tyr residue (Scheme 1.2B), and collapses to form the 
acetate leaving group and lysine (Scheme 1.2C). This process is followed by restoration of the 
active site. Although the active site residues are highly conserved among the metal-dependent 
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deacetylases, the class II HDACs, HDAC4, HDAC5 and HDAC7, have a histidine residue in 
place of the tyrosine residue (Y297), which explains their reduced deacetylase activities [28].                     
Further, the class I HDAC8 possesses a mono-valent ion containing second site (K+), which is 
close to the active site and is required for HDAC8 stability and deacetylase activity [25]. Due to 
the amino acid differences in the active sites of class I versus class II HDACs and the presence 
of a second metal in the active site in HDAC8, further work is needed to decipher the similarities 
and differences in the catalytic mechanisms of these enzymes.  It is important to note that 
efforts to understand the active site of the individual HDACs are frustrated by a lack of crystal 
structures and the fact that bacterially expressed HDAC proteins are inactive, except HDAC8 
[29, 30]. Lack of deacetylase activities for recombinant HDACs might be explained by the 
requirement of associated proteins to promote HDAC activity or folding (Section 1.4.3).  
1.4.4: HDAC associated proteins 
      Histone modifying enzymes are usually part of protein complexes that recognize and bind to 
specific histone modification(s) and are recruited at promoter regions leading to activation or 
silencing of target genes [31]. HATs are part of activator protein complexes.  Protein complexes 
with intrinsic HAT activities include the GNAT super family found in yeast, humans and mouse; 
the MYST family in yeast, humans and drosophila; the complex p300/CBP in various 
multicellular organisms; the SRC-1, ACTR and TIF2 family of nuclear receptor coactivators in 
humans and mice; TAFII250 in humans and mice, and the TFIIIC transcription factors in humans 
[32]. Transcription activators whose function is influenced by histone acetylation include; p53, c-
Myp, GATA-1, EKLF, E3F, HIV Tat, dTCF and the general transcription factors TFIIE and TFIIF 
[32]. Notably, the activity of the tumor suppressor gene p53 in cell cycle regulation and 
apoptosis is highly regulated and acetylation is one key regulatory mechanism.  In addition, 
acetylation of the basal RNA, III machinery, TFIIIC, by the p300/CBP-associated factor PCAF, is 
required for transcription initiation, whereby the initiation complex RNA polymerase III-TFIIIB 
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binds to the promoter region of DNA, further indicating that acetylation is not tied to histone 
proteins only [33]. 
      Similar to HATs, HDACs are part of transcriptional co-repressor complexes in vivo, for 
instance the Mi-2-NuRD, RbAp48-mSin3A or mSin3B complexes (known as Sin3 in yeast) and 
NCoR (nuclear hormone co repressor)/SMRT (silencing mediator of retinoid and thyroid 
receptors) [34, 35]. Mechanistically, HDACs associating with co-repressor complexes at 
promoter regions to deacetylate nucleosomal DNA of target transcription factors, leading to 
gene repression. The repressor activities of HDAC proteins involve DNA-bound transcription 
factors. For example, Mad:Max and Ume6 DNA-binding transcription repressors interact with 
the mSin3A/B complex which in turn recruits the mammalian deacetylases, HDAC1 or HDAC2, 
leading to gene repression [36]. Transcriptional repression by HDAC1 associating with the Mad-
Max heterodimer, is essential for suppression of cell transformation, which ties HDAC1 
deacetylase activity to cancer formation [37]. 
1.5: HDAC proteins in cancer 
       Aberrant epigenetic coding can lead to diseased states notably cancer, neuron-diseases, 
inflammation, and metabolic disorders [38-40].  Granted, clinically relevant therapies targeting 
epigenetic marks on histone proteins and DNA are currently in use and a lot more are in clinical 
trials, which make the epigenome a relevant area of research [41]. HDAC proteins have been 
implicated in a number of diseases, most notably cancer. Cancers are one of the leading 
causes of death not only in the United State but also in many other countries, according to the 
World Health Organization.  But despite the isolation and identification of the various HDAC 
isoforms, the individual functions of each HDAC isoform are poorly understood. However, 
overexpression of HDAC proteins has been observed in several cancers. The class I HDAC 
proteins, HDAC1, HDAC2, HDAC3 and HDAC8, are overexpressed in a number of cancers. 
HDAC1, HDAC2 and HDAC3 are overexpressed in colorectal cancer and higher levels of 
17 
 
 
expression correlate with reduced patient survival [42, 43]. Further, inhibiting HDAC1, 2, and 3 
expression by short interfering RNAs reduces tumor growth [43]. In patients with gastric cancer, 
HDAC1, HDAC2 and HDAC3 proteins are up regulated and higher levels of expression were 
seen in patients with advanced stage cancer suggesting that overexpression advanced tumor 
growth and aggressiveness [44, 45]. HDAC3 is over expressed in patients with lung cancer, as 
shown by gene micro-array profiling studies in lung cancer patients [46]. 
      A study involving prostate carcinomas showed that HDACs 1, 2 and 3 are up regulated and 
higher expression levels are associated with tumor cell proliferation and differentiation [47, 48]. 
HDAC1 is over expressed in pancreatic cancers and regulates the activity of the hypoxia 
induced transcription factor α, with higher levels of HDAC1 expression correlating to a decrease 
in patient survival [49].  Overexpression of HDACs 1 and 2 correlates with cervical dysplasia 
and invasive carcinoma [50].  Children with neuroblastoma have higher levels of HDAC8 and 
disease progression and death correlates with increasing HDAC8 expression levels [51].  
Overexpression of the class II HDAC 4 and 6 is seen in breast cancer tumors with HDAC6 
shown to be an estrogen-maintaining gene in patients with breast cancer [52].  Further, high 
levels of endogenous HDAC6 augment breast cancer motility and invasion [52]. HDAC6 is over 
expressed in oral squamous cell carcinoma [53]. HDACs 5 and HDAC 7 are up regulated in 
colorectal cancer [42]. 
      Despite the observed overexpression patterns of HDAC proteins in several cancers, little is 
known about the mechanisms via which HDAC overexpression lead to cancer formation and 
maintenance. Aberrant cell growth and proliferation are hallmarks for tumor genesis and HDAC1 
plays a crucial function. Specifically, HDAC1 is critical for proper cell differentiation and 
regulation of cell cycle check point genes [54]. Inhibition of HDAC1 and HDAC3, using small 
interring RNAs, led to a reduced proliferative phenotype in HeLa cells suggesting that HDAC1 
and 3 regulate the proliferation of cancer cell [55].  A similar study showed that siRNA 
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knockdown of HDAC1 and HDAC2 in prostate cancer cells renders them anti-proliferative and 
the cells fail to grow in vitro, further proving that HDAC1 and HDAC2 participate in maintaining 
proliferation of cancer cells [43]. These combined studies show that overexpression of HDAC 
proteins in cancer cells generally renders them proliferative. This phenomenon can be attributed 
to transcriptional repression of tumor suppressor genes and cell cycle check point genes by 
HDACs [56]. 
      Apart from regulating the proliferative state of tumors, HDAC proteins have been implicated 
in multi drug resistance. siRNA mediated inhibition of HDAC1 in drug resistant neuroblastoma 
cells rendered the cells sensitive to drug treatment in vitro [57]. In addition, HDAC proteins are 
indicators in the control of the biology of cancer cells by inhibiting apoptosis, angiogenesis of 
tumor cells from dormant to malignant states, cancerous cell migration and invasion, 
proliferation and dedifferentiation of cancerous cells.  Therefore, HDAC inhibitors have been 
explored as potential anti-cancer drugs. 
1.6: HDAC Inhibitors are cancer drugs 
      Because of their involvement in cancer biology, small molecules targeting HDAC proteins 
are attractive anti-cancer agents. HDAC inhibitors (HDACi) exert their inhibitory effects via 
binding to the active site pocket and the catalytic metal ion [58]. Two HDAC inhibitors, 
suberoylanilide hydroxamic acid (SAHA, Zolinza, Varinostat) and FK-228 (a depsipeptide) have 
been approved by the FDA for the treatment of cutaneous T-cell lymphoma (Figure 1.10) [59-
61]. Several HDACi are also in clinical trials for cancer treatment [62].  But, because the metal-
dependent HDAC proteins have conserved binding pockets and catalytic residues, most HDACi 
interact with most, if not all, of the HDAC family.  Efforts to characterize the inhibition patterns of 
HDACi are complicated by the fact that most recombinant purified proteins are inactive [63]. The 
observed inactivity with recombinant HDACs can be explained by the fact that HDAC proteins 
require associated protein partners to remain active, that are lacking in recombinant proteins. 
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      Non-selective HDAC inhibitors (pan inhibitors) are problematic due to the involvement of 
HDAC proteins in important cellular functions, and patients therefore typically experience a lot of 
side effects.  On the other hand, pan-inhibitors have been very useful in characterizing HDAC 
proteins and elucidating their functions in cancer cells. 
 
 
 
 
 
 
 
 
      HDACi are not only useful as anti-cancer agents but have been widely used as chemical 
tools to study HDAC proteins. The HDAC inhibitor trapoxin was used to identify and isolate the 
first human HDAC protein, human HDAC1, from nuclear cell extracts, paving the way for 
identification of the rest of the human HDAC family isoforms [7]. HDACi are indispensable tools 
in HDAC chemistry and the most commonly used ones are TSA and SAHA (Figure 1.10). The 
usage of HDACi as chemical tools has been demonstrated in many studies. For instance, 
treating murine erythroleukemia cells with HDAC inhibitors induced cell differentiation [64]. 
Malignant colorectal cancer cells displayed apoptotic effects upon treatment with the HDAC 
inhibitors TSA and butyrate [65]. The expression patterns of multiple genes involved in cell 
proliferation, cell differentiation and apoptosis were influenced by HDAC inhibitors, as shown by 
gene profiling studies [66, 67].  In vitro studies with HDAC 1, 2 and 3 treated with HDAC 
Figure 1.10: Structures of the HDAC inhibitors SAHA, TSA, MS-275 and FK-228. 
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inhibitors FK-228 and SAHA reduced ovarian cell growth and this was also observed using 
siRNA silencing [68]. 
1.7: This thesis project 
      To develop better anti-cancer drugs targeting HDAC proteins, more studies with HDAC 
proteins need to be done. Specifically, the individual roles of each HDAC isoform and their 
contributions to cancer are critical to aid in the design of isoform selective inhibitors. The long 
term goal of the HDAC project in the Pflum lab is to determine the individual roles of 
each HDAC protein and their contribution to cancer formation. As a first step towards 
achieving this goal, studies in this thesis project focus on HDAC1. HDAC1 is an attractive target 
for anti-cancer drugs because of its role in regulating cell proliferation and cell cycle, the main 
events that can lead to cancer development (see discussion in section1.6). 
      Due to a lack of crystallographic structural information on HDAC1, mutagenesis studies are 
a good alternative to give information on the involvement of amino acid residues in the active 
site on HDAC1 deacetylase activity. As discussed in section 1.4.2, the active site contains an 11 
Å hydrophobic channel where the long hydrophobic linker region of TSA and SAHA is 
sandwiched. Mutagenesis studies in this channel demonstrated that most of the amino acids 
within are crucial for deacetylase activity (Chapter 2, section 2.2.1) [69].  A 14 Å exit channel is 
next to the active site and has been hypothesized to be the exit patch for the acetate byproduct 
of the deacetylation reaction. Studies outlined in the second chapter of this dissertation 
seek to understand the roles of the amino acids in the 14 Å channel of human HDAC1 
using alanine scanning. 
      The third chapter of this thesis focuses on efforts towards understanding the involvement of 
HDAC proteins in cancer formation using small molecule HDAC inhibitors. Previous methods 
used to study HDAC1 include genetic methods, such as siRNA and knockout embryonic stem 
cells [54, 55]. HDAC1 knockout caused lethality on embryonic day 9.5 in mice, whereas siRNA 
required 48 hours time during which HDAC2 compensated for HDAC1. Therefore, genetic 
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methods are not suitable for characterizing HDAC1 in cancer biology. Small-molecule inhibitors 
are excellent alternatives to genetic methods. For example, small molecules influence protein 
activity quickly and do not give the cell time to express proteins, particularly other HDAC 
isoforms that might compensate for the abolished activity. It is also possible to evaluate a dose-
dependent effect for partial inhibition as opposed to total inhibition. Additionally, only the active 
site of the enzyme is affected, having the advantage of not affecting protein-protein associations 
which might be crucial to activity. With the advantages of inhibitors, the use of modified inhibitor 
analogues to characterize the individual functions of HDAC1 and their relevance to cancer 
formation is practical. Towards this goal, efforts to create the first HDAC1-inhibitor bump-
hole pair will be detailed in the third chapter. 
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Chapter 2 
2.1: Mutagenesis studies in HDAC1 14Å channel 
      HDAC1 is an attractive anti-cancer target (see section 1.5 chapter 1) and therefore HDAC1-
selective inhibitors would be valuable tools for studying the involvement of HDAC1 in cancer 
formation and provide better anti-cancer drugs. The lack of structural information for HDAC1 
has frustrated efforts to design selective inhibitors. Currently, HDAC inhibitor design relies on 
the crystal structure of a histone deacetylase like-protein (HDLP), which displays 35.2% 
sequence homology to HDAC1 [20]. A HDAC1 homology model based on HDLP revealed that 
the active site contains a hydrophobic 11 Å channel with a catalytic metal ion at the bottom of 
the channel [69]. HDAC inhibitors have been designed that fit in this long channel by making 
favorable hydrophobic interactions with amino acids lining the channel.  
      At the bottom of the active site and next to the catalytic metal ion is the 14 Å internal cavity 
whose function remains unclear [20, 21].  The 14 Å channel of Class 1 HDAC isotypes has been 
hypothesized to be the exit cavity for acetate following deacetylation [20, 21, 70]. The amino 
acids lining this cavity are very similar suggesting the role of the cavity is relevant to all class I 
HDACs. Computational and homology model studies identified charged amino acids that are 
likely to facilitate acetate escape by forming favorable ionic interactions (Figure 2.1) [71]. In one 
study, docking showed that both acetate and acetic acid localize next to the metal ion, R16 and 
R27 in HDLP (Figure 2.1) [21]. These interactions were not present in the 11 Å channel (Figure 
2.2) [21]. In contrast, similar studies with N-hydroxyacetamide, which is similar to HDAC 
inhibitors SAHA or TSA, revealed less binding. 
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      In addition to facilitating acetate escape, the internal cavity may act as an inlet for catalytic 
water following deacetylation to restore the active site configuration for the next cycle of 
catalysis, as illustrated in Figure 2.2 [21]. Further, residues located towards the solvent exposed 
regions of HDAC1 demonstrate flexibility, indicating that side chain movement near the solvent 
exposed region of the 14 Å channel could exchange cavity contents with the bulk water for the 
next cycle of deacetylation [20, 21].   
 
 
 
 
 
 
 
 
Figure 11: Docking acetate in the 14 Å channel of HDLP revealed important amino acids 
involved in acetate escape [21]. Acetate localized next to R16 (indicated by III) and R27 
(indicated by II) in HDLP presumably by forming ionic interaction, but failed to localize next to Zn 
(I) or in the 11 Å channel Similar results were shown with acetic acid (data not shown). Reprinted 
with permission from J. Med. Chem., 2004, 47 (13), 3409-17. 
 
Figure 12.2: Picture of internal cavity after deacetylation [21]. (A) While the free lysine 
chain leaves the 11 Å channel, the byproduct, acetate, passes through the 14 Å cavity (see 
arrows). (B) The catalytic center therefore is ready to accept water and an acetylated lysine for 
the next cycle of deacetylation. Reprinted with permission from J. Med. Chem., 2004, 47 (13), 
3409-17. 
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      The 14 Å channel has been exploited in inhibitor design. Several isoform selective HDACi 
designed to fit the 14 Å channel have been created [18, 19]. In one study, docking MS-275 into 
a HDAC1 homology model revealed that a large aromatic substituent on the metal binding 
moiety could access the 14 Å channel [19]. In addition, the presence of M30 and C151 
suggested that para-thienyl substituted amino benzamide MS-275 derivatives could benefit from 
potential sulfur interactions. This led to the synthesis of compounds 1 with an IC50 of 0.02 µM 
and 0.5 µM against recombinant HDAC1, and 2 respectively (5-fold selectivity for HDAC1 over 
HDAC2) but is non selective towards HDAC3 and 8. Further studies led to the synthesis of 
compounds 2 (IC50=0.06 µM for HDAC1 and IC50=0.2 µM for HDAC2) and 3 (IC50=0.05 µM for 
HDAC1 and IC50=0.2 µM for HDAC2), which represents 100-400-fold selectivity for HDAC1 and 
2 over HDAC3 and 8 (both compounds 2 and 3 have IC50>20 µM for HDACs 3 and 8). The 
observed increases in selectivity are attributed to additional beneficial interactions between MS-
275 derivatives and the enzyme resulting from potential sulfur interactions with amino acids 
located in the 14 Å channel. 
 
 
 
 
 
 
 
 
 
Figure 13: HDAC1 and 2 selective MS-275 derivatives designed to fit the 14Å channel [19]. 
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      In a separate study, several other HDAC inhibitors designed to fit the 14 Å channel were 
created (Figure 2.4) [72]. Compound 4 was 30-fold selective for HDAC1 over HDAC2 (HDAC1 
IC50=6 nM and HDAC2 IC50=190 nM) and is only weakly bound to HDAC3 (IC50=27 µM) and 
HDAC8 (IC50=31 µM).  Similarly, compound 5 was 10-fold selective for HDAC1 (IC50=10 nM) 
over HDAC2 (IC50=105 nM) with very weak HDAC3 and 8 affinity (IC50>50 µM). Combined, both 
studies suggest that isoform selective HDAC inhibitors can be designed to bind the 14 Å 
channel [18].  
 
 
 
 
 
With no structural information for HDAC1, the role of the 14 Å channel in acetate binding and 
substrate/inhibitor binding is still unclear. Without crystallographic information, mutagenesis can 
offer insight into the influence of amino acid residues in the 14 Å cavity to HDAC1 activity.  
2.2: Prior HDAC1 mutagenesis studies in the Pflum lab 
      Residues lining the 11 Å channel of HDAC1 form hydrophobic contacts with the acetylated 
Lys substrate in the active site (Chapter 1, figure 1.7). Amino acids lining the 11 Å channel are 
well conserved among the HDAC isoforms suggesting that their roles are relevant to all isoforms 
(Figure 2.5). Previous mutagenesis studies in the 11 Å channel of HDAC1 revealed that 
residues in this channel influence enzymatic activity (Figure 2.6) [69].  
  
Figure 14: HDAC1 and 2 selective MS-275 derivatives designed to fit the 14 Å channel [72]. 
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      To study the 11 Å channel amino acids, a homology model was used to identify nine amino 
acids that line this channel in human HDACI. An alanine scan for these nine amino acid 
residues identified eight residues crucial for enzyme activity (Figure 2.7) [69]. Specifically, 
mutating H28, P29, D99, G149, F150, Y204, F205 and L271 to alanine led to a 62-91% 
reduction in HDAC1 enzymatic activity compared to wild type (Figure 2.7A) [69]. The only 
exception was the E98A mutant, located in the solvent exposed region of HDAC1, that 
Figure 15: A Clustal W alignment of the residues lining catalytic domains of class I, II and 
IV human HDAC proteins [69]. Amino acid residues located in the substrate binding region (the 
11 Å channel) are shown.  Highlighted in red are the residues that differ from the most 
conserved residue at the specified position. The numbering on top is for HDACI.  
 
Figure 16: A human HDAC1 homology model showing residues lining the 11 Å channel of 
HDACI [69]. Channel residues are shown as ball and stick structures. The gray ball shows the 
catalytic zinc, whereas the yellow, red and blue represent carbon, oxygen, and nitrogen atoms 
respectively. Reproduced with permission from J. Med. Chem., 2008, 51 (18), 5542-51. 
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maintained deacetylase activity to levels comparable to HDAC1 (Figure 2.7A [69]. Further, 
mutating channel residues did not compromise HDAC1 binding to its associated proteins 
(Figure 2.7B). These combined data suggest that residues lining the 11 Å channel govern 
substrate binding and that mutations lead to a reorganization of the channel residues which 
compromise HDAC1 deacetylase activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Residues lining the 11 Å channel of HDAC1 promote enzyme activity but not 
protein associations [69]. (A) HDAC1 wild-type or alanine mutants were expressed as FLAG-
tagged fusion proteins and were immunoprecipitated with anti-FLAG-agarose resin. The 
immunoprecipitated proteins were used in fluorescence HDAC assays (histogram). The mean 
percent activity of five independent trials compared with that of the wild-type protein (100%) with 
standard error is shown. The immunoprecipitated proteins were also separated by SDS-PAGE 
and were probed with anti-FLAG (gel image) to ensure that equivalent protein quantities were 
used (Figure A.1). (B) Immunoprecipitated proteins in part A were further probed with anti-
mSin3A, anti-RbAp48, and anti-FLAG to assess protein association. Reproduced with 
permission from J. Med. Chem., 2008, 51 (18), 5542-51. 
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      Studies outlined in this chapter were geared towards understanding the importance of amino 
acid residues in the 14 Å internal cavity for HDAC1 activity. We used alanine scanning 
mutagenesis and substitution mutagenesis to determine the importance of channel residues to 
HDAC1 activity. Further, we performed an acetate competition assay to determine whether 
alanine mutants affect HDAC1 binding to acetate. Our results suggest that amino acids lining 
the 14 Å channel are important to maintain HDAC1 catalytic activity and that mutating them to 
alanine leads to a loss in activity. The acetate competition experiments reveal that several 
residues affect the interaction of HDAC1 with acetate.  The mutagenesis studies identified 
amino acid residues involved in acetate or inhibitor binding and will aid in HDAC1 inhibitor 
design that includes the 14 Å channel. 
2.3: Results 
2.3.1: Residues in the 14Å channel of HDAC1 are critical for activity 
       Computational and homology studies have predicted that in HDAC1 Y23 (aligned with R16 
in HDLP) and R34 (aligned with R27 in HDLP) form a charged pocket in the 14 Å channel and 
bind to and thereby stabilize the acetate by-product of the deacetylation reaction (Figure 2.1 and 
2.2) [21]. The polar residues C151 and Y24 line the other side of the cavity and are likely to 
influence acetate binding and restoration of the active site configuration (Figure 2.2).  In 
addition, these four amino acids might influence substrate binding and orientation of the active 
site due to their close proximity to the active site. Not surprisingly, C151 and R34 are strictly 
conserved among all class 1 isoforms, while Y23 and Y24 maintain 75% similarity (Figure 2.8B), 
indicating that the role of the 14 Å channel is relevant to all class 1 HDACs. 
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     To determine the influence of Y23, Y24, R34 and C151 in the 14 Å channel on HDAC1 
enzymatic activity, each amino acid was individually mutated to alanine. Alanine mutants or the 
wild-type were expressed in T-Ag Jurkat cells as FLAG-tagged fusion proteins, 
immunoprecipitated with α-FLAG agarose beads, and tested for deacetylase activity using an in 
vitro fluoresence assay (Figure 2.9). The catalytically inactive mutant H141A was included for 
comparison purposes [20].  
      These alanine mutants each significantly influenced HDAC1 catalytic activity. The highly 
conserved R34 and C151 alanine mutants demonstrated only 31±6.5% and 21±4.5% remaining 
activity, compared to the wild type (100%) and which is comparable to the inactive H141A 
(19%±1.5). Mutating the two Tyr residues, Y23 and Y24 to alanine led to a 34± 7.0% and 25± 
6.0% catalytic activity, respectively, compared to the wild type (100%). The HDAC1 homology 
model predicts that R34 and C151 are closer to the active site than Y23 and Y24, which are 
closer to the solvent exposed region of the 14 Å channel (Figure 2.8). These alanine scan 
Figure 18: (A) Amino acid residues in the acetate-escape patch of HDAC1.  The four amino 
acids (stick structures) lining the 14 Å channel of an HDAC1 homology model are shown.   (B) 
Amino acid residues lining the 14 Å channel are shown for class I HDACs and HDLP. The 
catalytic domains of class 1 HDAC isoforms were aligned used Clustal W.  Residues highlighted 
in red differ at Y23 (HDAC1) and Y24 (HDAC1). 
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results suggest that Y23, Y24, R34 and C151 are critical to maintain the catalytic activity of 
HDAC1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      To study the influence of other amino acids lining the 14 Å channel on catalytic activity, the 
HDAC1 homology model was used to identify V19, M30, I35, R36, S113, L139 and Y303 for 
further analysis (Figure 2.10). With the exception of R36, most of these amino acids are 
hydrophobic or polar, and are therefore not expected to bind to acetate. Because of their 
Figure 19: Y23A, Y24A, R34A and C151A mutants affect HDAC1 deacetylase activity, but 
not protein association. (A) Wild type or mutant proteins were expressed in T-Ag Jurkat cells 
as FLAG-tagged fusion proteins, immunoprecipitated with anti-FLAG-agarose beads, and tested 
for catalytic activity using an in vitro fluorescence assay (histogram) or separated on SDS-PAGE 
and probed with anti-FLAG antibody (gel image). The histogram shows the mean percent of at 
least four independent trials, which were normalized to wild type deacetylase activity (set to 
100%). The standard error is shown as error bars (Table A.1). (B). Immunoprecipitated wild type 
and alanine mutants in A were further probed with anti-FLAG, anti-RbAp48 and anti-mSin3A to 
assess protein association. 
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location in the 14 Å channel and proximity to the active site, these seven amino acids may 
influence substrate binding or restoration of the active site configuration.  
 
 
 
 
 
 
 
 
      To determine the influence of seven additional amino acids in the 14 Å channel on HDAC1 
enzymatic activity, each amino acid was individually mutated to alanine, over expressed, 
immunoprecipitated, and tested for activity as discussed earlier. These alanine mutants all 
significantly reduced HDAC1 catalytic activity (Figure 2.11). The strictly conserved Y303 alanine 
mutant displayed 6.7±1.5% remaining activity relative to the wild type HDAC1 (100%). The 
homology model predicts that Y303 is close to the active site, near the catalytic metal ion 
(Figure 2.10). The dramatic loss of activity in the alanine mutation suggests that Y303 promotes  
HDAC1 deacetylase activity. The alanine mutations of hydrophobic residues V19, I35 and L139, 
which display 50% similarity among the class 1 isotypes, displayed between 5-39% deacetylase 
activities suggesting that all are important for HDAC1 deacetylase activity. Mutation of the 
amino acids M30 and S113 to alanine resulted in 19±6% and 62±4% deacetylase activities. The 
R36A mutant had 25±4% remaining activity, which is comparable to the inactive H141A mutant 
(19±1.5%).  The combined mutagenesis data suggests that except for S113, the other six amino 
Figure 20: Residues in the 14 Å channel of HDAC1 (A).The seven additional amino acids 
(stick structures) lining the 14Å channel of the HDAC1 homology model are shown.   (B) 
ClustalW alignment of the amino acids noted in A.  Highlighted in red are the residues differing 
at each position. 
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acids in the 14Å channel are critical for maintaining HDAC1 enzymatic activity but do not appear 
to be involved in acetate release. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: The 14 Å channel alanine mutants affect HDAC1 deacetylase activity, but have 
no effect on protein association. (A) Wild type or mutant proteins were expressed in T-Ag 
Jurkat cells as FLAG-tagged fusion proteins, immunoprecipitated with anti-FLAG-agarose 
beads, and tested for catalytic activity using an in vitro fluorescence assay (histogram) or 
separated on SDS-PAGE and probed with anti-FLAG antibody (gel image). The histogram 
shows the mean percent of at least four independent trials that were normalized to wild type 
deacetylase activity (set to 100%). The standard error is shown with error bars. (B) Co-
immunoprecipitation of alanine mutants in A with, anti-FLAG, anti-RbAp48 and anti-mSin3A to 
assess protein association. 
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2.3.2: HDAC1 rescue mutants are inactive 
      According to computational and homology studies, the strictly conserved R34 is located 
closer to the active site, whereas the poorly conserved R36 residue is adjacent to R34 but 
farther  from the active site in HDAC1 (Figures 2.6 and 2.8) [69].  The acetate by-product of the 
deacetylation reaction could form favorable ionic interactions to R34 and Y23 (similar to R16 in 
HDLP) located farther from the active site and close to the solvent exposed region of the 14 Å 
channel. These computational studies predict that acetate is exchanged with the bulk water 
outside the channel. Substitution of a similar charged functional group capable of forming ionic 
bond at R34 or R36 in HDAC1 could maintain enzymatic activity.  Similarly, the C151 residue 
(located next to the catalytic metal ion and in the 14 Å channel) could be replaced by serine with 
a similar polar functional group, which could maintain interactions with acetate or the active site. 
Additionally, to probe the importance of the aromatic phenyl group of Y23, 24 and 303 in 
HDAC1, Y23F, Y24F and Y303F substitution mutants were created. In this case, if aromaticity is 
critical, aromatic amino acids should replace tyrosine.  
       To test the rescue mutations, Y23F, Y24F, R34K, R36K, C151S and Y303F single point 
mutants were expressed in T-Ag Jurkat cells as FLAG-tagged fusion proteins, 
immunoprecipitated with FLAG-agarose beads, and tested for deacetylase activity using an in 
vitro fluoresence assay, as described earlier. The substitution mutants were unable to restore 
HDAC1 catalytic activity except for the Y24F mutant (Figure 2.12). R34K, R36K and C151S 
HDAC1 mutants demonstrated 17±3.0%, 33±3.5% and 30±1.0% remaining activity respectively. 
Mutating the residues Y23, Y24 and Y303 to Phe led to 12±3.5%, 56±9.0% and 38±4.0% 
deacetylase activity respectively. Collectively, these mutagenesis data suggest that Y23, Y24, 
R34, R36, C151 and Y303 are uniquely suited to promote HDAC1 deacetylase activity, and that 
F partially substitutes for Y24 and Y303 in HDAC1. 
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2.3.3: Mutation of amino acids lining the 14 Å channel of HDAC1 does not disrupt protein 
association 
       The mammalian co-repressor complexes mSin3A and RbAp48 tie HDAC1 to promoter-
bound transcription factors, leading to transcriptional gene silencing (discussed in section 1.4.3 
chapter 1) [70, 73-75]. The binding of HDAC1 to co-repressors not only recruits the deacetylase 
to promoter regions but also leads to an increase in deacetylase activity [73]. Our results 
suggest that alanine and substitution mutants abolish HDAC1 activity. It is therefore possible 
that mutations lead to protein misfolding and/or that mutant proteins fail to bind to co-repressor 
Figure 22: HDAC1 Y23F, Y24F, R34K, R36K, C151S and Y303F substitution mutants are 
inactive. (A) Wild type or mutant proteins were expressed in T-Ag Jurkat cells as FLAG-tagged 
fusion proteins, immunoprecipitated with anti-FLAG-agarose beads, and tested for catalytic 
activity using an in vitro fluorescence assay (histogram) or separated on SDS-PAGE and probed 
with anti-FLAG antibody (gel image). The histogram shows the mean percent of at least three 
independent trials that were normalized to wild type deacetylase activity (set to 100%). The 
standard error is shown as error bars (Table A.2). (B) Co-immunoprecipitation of mutants in (A) 
with anti- FLAG, anti- RbAp48 and anti-mSin3A to assess protein association. 
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complexes. To test whether the loss in activity observed in mutant proteins was a result of 
failure of the mutant proteins to bind to its associating partners, biochemical purification was 
performed. Alanine and substitution mutants were immunoprecipitated with FLAG-agarose 
beads, separated on SDS-PAGE, and probed with anti-mSin3A or anti-RbAp48 antibodies.  
Alanine and substitution mutants displayed equal co-immunoprecipitation activities independent 
of deacetylase activity (Figure 2.9B, 2.11B and 2.12B). The inactive H141A recovered similar 
levels of mSin3A and RbAp48 comparable to the wild type as previously reported [69]. 
Collectively, our results suggest that the loss in activity in 14Å channel is not due to a failure of 
mutant proteins to bind to the co-repressor complexes. 
2.3.4: R34 and R36 affect interaction of HDAC1 with acetate 
       To facilitate passage of acetate through the 14 Å channel, computational studies predicted 
that charged amino acids R34 and R36 in HDAC1 would form favorable ionic/hydrogen bond 
interactions with acetate [21]. Polar residues Y23, Y24, C151 could also hydrogen bond to 
acetate [70].Further, side chain movement of Y23 and Y24 located towards the solvent exposed 
region of the 14 Å channel could help exchange acetate with the bulk water solvent [21, 70]. Our 
mutagenesis results demonstrate that mutations of the amino acids thought to bind to acetate 
abolish HDAC1 enzymatic activity.  
       To determine the influence of mutant proteins to acetate binding in HDAC1, acetate 
inhibition of the activities of Y23, Y24, R34, R36, and C151 mutants were determined and 
compared to wild type. The F205Y mutant located in the 11 Å channel was included as a control 
because it should not affect acetate binding [69]. Mutant or wild type proteins were 
immunoprecipitated with FLAG-agarose beads and the extent of inhibition by acetate was 
determined at constant substrate concentration. All 14 Å tunnel mutations displayed altered 
acetate inhibition. The R34A and R36A mutants displayed 1.7 and 2.8 fold reduced IC50 values 
(12 mM and 15 mM, respectively) compared to the wild type (7.2 mM) and F205Y (7.5 mM) 
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controls (Figure 2.13). Similarly, the Y23A, Y24A and C151A mutants displayed close to 2-fold 
reduction in acetate binding compared to wild type (Figure 2.14). Collectively, these acetate 
competition data suggest that both charged and polar amino acid residues in this channel 
influence HDAC1 binding to acetate and confirms the involvement of these amino acids in 
acetate binding or release. 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
Figure 23: R34 and R36 mutations affect HDAC1 binding to acetate. Wild type or mutant 
proteins were expressed in T-Ag Jurkat cells as FLAG-tagged fusion proteins, 
immunoprecipitated with anti-FLAG-agarose bead, and tested for catalytic activity in the 
presence of varying concentrations of acetate (0-200 mM). The standard error for at least 
three trials is shown. (Table 1.1). 
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Table 1.1: IC50 values on acetate inhibition of HDAC1 and mutant proteins
a 
HDAC1 IC50 (mM) 
Wild type 7.2 ± 0.5 
 
Y23A 21 ± 2 
Y24A 19 ± 1 
R34A 12 ± 0.3 
R36A 15  ± 1 
C151A 13 ± 1 
F205Y   7.6 ± 1.1 
aCalculated from at least three trials; errors are the standard error of the mean. 
 
 
 
 
 
 
 
 
 
Figure 24: Y23, Y24 and C151 affect HDAC1 binding to acetate. Wild type or mutant proteins 
were expressed in T-Ag Jurkat cells as FLAG-tagged fusion proteins, immunoprecipitated with 
anti-FLAG-agarose bead, and tested for catalytic activity in the presence of varying 
concentrations of acetate (0-200 mM). The standard error for at least three trials is shown 
(Table 1.1). 
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2.4: Discussion 
      The 14 Å channel of Class 1 HDAC isotypes has long being hypothesized to be the exit 
cavity for acetate release by deacetylation [20, 21, 70]. The amino acids lining this cavity are 
very similar among the HDAC isoforms, suggesting the role of the cavity is relevant to all 
HDACs proteins. In one study, docking showed that both acetate and acetic acid localize next to 
the metal ion, and amino acids R16 and R17 in HDLP. In contrast, in similar studies, N-
hydroxyacetamide, which is related in structure to HDAC inhibitors SAHA or TSA, was bound to 
the 11 Å channel,but less to the 14 Å channel  [21].  In addition, amino acids located towards 
the solvent exposed regions of HDAC1 demonstrate flexibility, indicating that side chain 
movement of these amino acids could help exchange cavity contents with bulk water for the 
next cycle of deacetylation [20, 21]. To date, no experimental data confirm these speculations 
with HDAC1. 
      An alanine scan was used to determine the influence of amino acid residues lining the 14 Å 
channel of HDAC1 in enzymatic activity and binding to acetate [22, 69]. HDAC1 V19A, Y23A, 
Y24A, M30A, R34A, I35A, R36A, L139A, C151A and Y303A mutants reduced HDAC1 
deacetylase activity significantly to levels ranging from 6 to 34% compared to the wild type. The 
S113A mutant, which is located near the solvent exposed region of the internal cavity, maintains 
significant deacetylase activity at 61% compared to the wild type (100%).  Because polar and 
charged residues lining the 14 Å channel of HDAC1 are implicated in acetate binding and 
release, more conservative mutations were examined to see if they could restore deacetylase 
activity. These mutants also displayed reduced deacetylase activities suggesting functional 
group specificity. Y24F is the only mutant that maintained a significant deacetylase activity at 
56% compared to that of the wild type. These combined mutagenesis studies suggest that the 
14 Å channel is critical to maintain HDAC1 activity and influence acetate binding and release. 
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      Mutating the 14 Å cavity residues does not globally affect HDAC1 structure as shown by the 
protein association studies. The loss in enzymatic activity for mutant proteins can therefore be 
attributed to two possibilities. One, mutating channel residues might influence substrate binding 
and govern the organization of the active site residues, which ultimately affect HDAC1 activity. 
Alternatively, mutating channel residues might influence the release of the acetate by-product. 
To probe this hypothesis further, we determined the influence of mutation on HDAC1 binding to 
acetate.  Both polar and charged residues showed a two-fold reduction in the half-maximal 
inhibition by acetate compared to the wild type. It is likely that mutating these residues remove 
key contacts required for acetate binding and release. These findings are consistent with 
previous work on HDAC8, where acetate competition assay with recombinant HDAC8 R37A 
resulted into 160-fold difference in IC50 values (HDAC8R37A IC50 of 400 mM versus the HDAC8 
wild type IC50 of 2.5 mM) [22]. The small differences observed here with HDAC1 could be a 
result of mammalian proteins versus bacterially-expressed proteins in the two separate studies. 
Combined, our results indicate that the 14 Å channel mutants do not significantly alter the active 
site configuration, but rather affect the substrate binding and acetate release.   
      HDAC1 has been linked to certain cancers, making it an attractive target for cancer therapy. 
Characterization of HDAC1 structure will aid in drug-design efforts and will facilitate the 
understanding of its involvement in cancer formation. In addition, HDAC1 selective inhibitors 
may be valuable cancer therapeutics. The lack of structural information on the HDAC1 active 
site has frustrated efforts to design HDAC1 selective inhibitors. Structural characterization of 
HDAC1 has been hindered by lack of active enzyme from heterologous bacteria culture [76]. As 
an alternative, mutagenesis offers insight into the influence of amino acid residues in the 
enzyme pocket to HDAC1 activity. The combined mutagenesis data confirm the importance of 
V19, Y23, Y24, M30, R34, I35, R36, S113, L139, C151 and Y303 in the 14 Å channel of 
HDAC1, as predicted earlier[21,71]. 
40 
 
 
      The mutagenesis studies in this work will aid in the design of HDAC1 selective inhibitors. 
Importantly, selective HDAC1 inhibitors designed to fit the 14Å channel have been created [19]. 
Subtle differences in amino acids give rise to distinct channel regions and can be exploited to 
design selective HDAC1 inhibitors as previously reported [19, 71]. The acetate competition 
results suggest that designing HDAC1 inhibitors with acetate mimics targeting interactions with 
Y23 can create a HDAC1 selective inhibitor.  Future inhibitor design which includes the 14Å 
channel will benefit from these findings. 
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2.5: Experimental procedures 
2.5.1:  General biochemical equipment 
       Equipment available in the Pflum lab includes centrifuges (Eppendorf models 5415D and 
5810R), bacterial incubator/shaker (New Brunswick Scientific C25 Incubator Shaker Classic 
Series), Tecan GENios Plus spectrophotomer, Biorad gel electrophoresis systems and an 
Eppendorf Mastercycler Gradient. 
2.5.2: Single point mutagenesis 
      Asymmetric was used to create HDAC1 single-point mutants using the primers shown 
below; mutants were cloned into the pBJ5HDAC1-Flag expression plasmid using Not1 and 
EcoR1 restriction sites [70].  All mutants were confirmed by DNA sequencing. The primers used 
were as follows (mutation bolded): 
pBJ5 Not1 start:  GCCAGAATGCGGCCGCATGGCGCAG 
pBJ5 153 rev:  TATCATGTCTGGATCCGG 
HDAC1 V19A rev: CATCCCCGTCGTAGTAGTAACAGAC 
HDAC1 V19A for:  GTTACTACTACGACGGGGATGCTGGAAATTACTATTATGG 
HDAC1 Y24A rev: GTAATTTCCAACATCCCCG 
HDAC1 Y23A for:  CGGGGATGTTGGAAATTACGCATATGGACAAGGCCACCCAATG AAGCC 
HDAC1Y23Ffor: CGGGGATGTTGGAAATTACTTCTATGGACAAGGCCACCCAATGAAGCC 
HDAC1 Y24A for: CGGGGATGTTGGAAATTACTATGCAGGACAAGGCCACCCAATGAAGCC 
HDAC1 Y24F for: CGGGGATGTTGGAAATTACTATTTCGGACAAGGCCACCCAATGAAGCC 
HDAC1 M30A rev: GGGTGGCCTTGTCCATAATAG 
HDAC1M30A for: GGACAAGGCCACCCAGCGAAGCCTCACCGAATC 
HDAC1 R34A rev: GGCTTCATTGGGTGGCCTTGTCC 
HDAC1 R34A for:  GGCCACCCAATGAAGCCTCACGCAATCCGCATGACTCATAATTTGCTG 
 HDAC1 R34K for:  GGCCAC CCAATGAAGCCTCACAAGATCCGCATGACTCATAATTTGCTG 
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 HDAC1 I35A rev:  CGGTGAGGCTTCATTGGGTGG 
 HDAC1 I35A for: CCCAATGAAGCCTCACCGAGCCCGCATGACTCATAATTTGCTGC 
 HDAC1 R36A for: CCCAATGAAGCCTCACCGAATCGCCATGACTCATAATTTGCTGC 
 HDAC1 R36K for:  CCCAATGAAGCCTCACCGAATCAAAATGACTCATAATTTGCTGC 
 HDAC1 S113A rev: CAACTGACAGAACTCAAACAGGCC 
 HDAC1 S113A for: GGCCTGTTTGAGTTCTGTCAGTTGGCAACTGGTGGTTCTGTGGC 
 HDAC1 L139A rev: GCCCCCAGCCCAATTCACAGCG 
 HDAC1 L139A for: GGGCTGGGGGCGCGCACCATGCAAAGAAGTCCGAGGC 
 HDAC1 C151A rev: GAAGCCAGATGCCTCGGACTTC 
 HDAC1 C151A for: GTCCGAGGCATCTGGCTTCGCTTACGTCAATGATATC 
 HDAC1 C151S for: GTCCGAGGCATCTGGCTTCTCTTACGTCAATGATATC 
 HDAC1 Y303A rev: CCACCGCCTCCCAGCATCAGC 
 HDAC1 Y303A for: GGGAGGCGGTGGGCTCACCATTCGTAACGTTGCCCGG 
 HDAC1 Y303F for: GGGAGGCGGTGGTTTCACCATTCGTAACGTTGCCCGG 
2.5.3: Polymerase Chain Reaction (PCR) 
       Two-step (touchdown PCR program) PCR was used to generate PCR inserts with the 
mutagenic primers described in section 2.5.2.  A typical reaction mixture contained the following 
reagents: water (30 µL), DMSO (5 µL), 10X Pfu buffer (5 µL of 200 mM Tris, 100 mM (NH4)2SO4, 
100 mM KCl, 1% TritonX-100, 20 mM MgSO4, 1 mg/mL BSA, pH 8.8), DNA plasmid template (1 
µL of 0.5 µg/µL), forward primer (1 μL of 25 µM), reverse primer (1 μL of 25 µM), and dNTPs 
(2µL of 10 mM ; 2.5mM of each base). PCR reaction mixtures were mixed thoroughly by 
pipetting and then heated in a thermocycler (Eppendorf Mastercycler Gradient) for 1 minute at 95 
°C and 2 µL Pfu enzyme was added.  After addition of the enzyme, initial 10 cycles of the 
touchdown program were run as follows: 1 minute 95 °C, 1 minute annealing, 2 minutes 
elongation at 72°C. The initial and final annealing temperatures in the 10 cycles were 60 °C and 
50 °C respectively with lowering of the temperature by 1 °C per cycle. After another 25 cycles at 
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the final annealing temperature of 50 °C, the PCR cycles ended with a 10 minute elongation 
period at 72 °C before cooling to 4 °C. DNA products were purified by gel electrophoresis as 
described below in section 2.5.4. 
       The second step PCR was similarly run to create the full length HDAC1-FLAG mutant insert 
for homologous recombination using 5 µL of gel purified PCR1 products to replace the DNA 
template and the volume of water adjusted to final 50 µL total volume. PCR2 products were 
similarly gel purified (section 2.5.4). 
2.5.4: DNA agarose gel electrophoresis and gel purification 
       Gel electrophoresis was done using 1% agarose in 1X Tris-Acetate-EDTA buffer (TAE; 40 
mM Tris, 20 mM acetic acid, 1mM EDTA, pH 8.8, 0.5 µg/mL ethidium bromide) for 60 minutes at 
120V Separated DNA was purified using the QIAgen gel extraction kit (cat # 28704) and used for 
homologous recombination (section 2.5.6). 
2.5.5: Restriction digest 
       pBJ5HDAC1[70] was digested with EcoRI and NotI restriction enzymes (both from 
Promega). The restriction digest reaction contained, pBH5HDAC1 (50 ng of 1 µL) buffer H (2 µL; 
Promega), BSA (1 µL of 0.1 mg/mL), of Not1 and EcoRI (1 µL each) and water (14 µL). The 
reaction mixture was incubated for 2 hours at 37 °C with shaking at 250rpm. The DNA was 
recovered by gel electrophoresis (section 2.5.4) followed by extraction using the QIAgen gel 
extraction kit. 
2.5.6: Homologous recombination in KC8 cells 
       KC8 cells (50 µL section 2.5.10) were mixed with PCR insert (5 µL; section 2.5.3), 
restriction-digested DNA (5 µL; section 2.5.5), KCM buffer (10 µL of 0.1M KCl, 30 mM CaCl2, 50 
mM MgCl2) and 30 µL water. The mixture was incubated on ice for 20 minutes followed by a 60-
90 second heat shock at 42 °C. The cells were then cooled on ice for 2 minutes, before 500 µL of 
LB medium (1% peptone, 0.5% yeast extract and 1% NaCl) was added. Cells were incubated for 
90 minutes at 37 °C with shaking at 250 rpm. Cells were collected by spinning at 13200 rpm for 
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10 minutes and all but 100 µL of the supernatant was removed. The remaining media was used 
to resuspend the cell pellet followed by plating on 20 µg/mL kanamycin (to select for KC8) and 
50 µg/mL ampicillin LB agar plates (to select for pBJ5HDAC1). The cells were grown overnight at 
37 °C.  The DNA from individual colonies was mini-prepped as described in section 2.5.8 and 
sequenced by the University of Michigan DNA sequencing core. 
2.5.7: Bacterial plasmid transformation 
       Wild type pBJ5HDAC1-Flag or mutant expression plasmids were transformed into 
chemocompetent DH5α E. coli (section 2.5.9). DH5α competent cells (100 µL) were thawed on 
ice and 1 µL plasmid DNA was added and mixed. Next, the solution was incubated for 20 
minutes on ice and heat-shock treated for 60-90 seconds at 42 °C. The cells were quickly 
transferred into ice for 2 minutes, after which 0.5 mL of LB media was added.  The cells were 
grown for 1 hour at 37 °C with shaking at 250 rpm. Cells were collected by spinning at 13000 rpm 
for 10 minutes and all but 100 µL of the supernatant removed by aspiration. The cell pellet was 
resuspended into the remaining 100 µL and plated on LB agar plates containing 50 µg/mL 
ampicillin. Plated cells were grown overnight at 37 °C.  
2.5.8: Plasmid mini and midi-preps 
       One colony of DH5α cells expressing wild type pBJ5HDAC1-Flag or mutant expression 
plasmids (section 2.5.7) or KC8 cells containing a new clone (section 2.5.6)  was inoculated into 
5 mL (mini-prep) or 100 mL (midi-prep) LB containing 50 µg/mL ampicillin.  The culture was 
grown overnight at 37 °C at 250 rpm. Cells were recovered by spinning at 13200 rpm for 10 
minutes at 4 °C. The supernatant was removed by aspiration and the cell pellet was 
resuspended into 300 µL (mini-prep) or 4 mL (midi-prep) cold P1 buffer (50 mM Tris-Cl, pH 8.0, 
10 mM EDTA, 100 μg/mL RNAse A). Room temperature 300 µL (mini-prep) or 4mL (midi-prep)  
P2 buffer (200 mM sodium hydroxide, 1% SDS) was added and mixed by inversion prior to 
incubation for 5 minutes at room temperature with constant gentle mixing. Cold P3 buffer (300 
µL for mini-prep or 4 mL for midi-prep of 3.0 M potassium acetate, pH 5.5) was added, mixed by 
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inversion, and incubated on ice for 15 minutes (inversion every 5 minutes). The cell debris was 
removed by spinning at 13200 rpm for 10 minutes and the supernatant was loaded on a QIAgen 
column (midi-prep; needed for mammalian transfection) or a pre-chilled tube containing 540 μL 
of isopropanol. Midi-prep DNA was prepared as per the Qiagen protocol. The mini-prep was 
incubated on ice for 5 minutes after which the DNA was collected by spinning at 13200 rpm for 
10 minutes, the supernatant was removed by aspiration, and the DNA was redissolved in 20 μL 
water and stored at -20 °C. 
2.5.9: Preparation of chemocompetent  DH5α Blue E. coli  
       DH5α E. coli was made chemocompetent by calcium chloride treatment to allow for plasmid 
uptake or transformation for subsequent replication to produce large amounts of plasmid.  A 
single colony of DH5α was inoculated into 25 mL LB and grown overnight at 37 °C with shaking 
at 250 rpm. On day 2, 4 mL of the overnight culture was diluted into 400 mL LB and similarly 
grown until OD600=0.375.  Portions of the growth culture (50 mL) were transferred into 50 mL 
pre-chilled centrifuge tubes and cooled on ice for 10 minutes, followed by spinning at 4000 rpm, 
for 10 minutes at 4 °C. The liquid supernatants were removed via aspiration and the cell pellets 
were washed 3 times with 10 mL cold CaCl2 solution (60 mM CaCl2, 10 mM PIPES, and 15% v/v 
glycerol). After the last wash, the cell pellets were resuspended in 2 mL of CaCl2, split into 100 
µL aliquots, and stored at -80 °C until use. 
2.5.10: Preparation of KC8 competent cells 
       KC8 cells were obtained from the Finley lab (Wayne State University).  An overnight culture 
(5 mL) grown at 37 °C with 250 rpm shaking was diluted into 500mL LB media. The cells were 
further grown for about 3-4 hours at the same growth conditions until OD600 reached about 0.5. 
Cells were recovered by spinning at 3500 rpm for 15 minutes at 4 °C and the LB was poured 
out. Cells were resuspended into 25 mL cold LBSB (LB diluted with HCl to pH 6.1, 10% (w/v) 
PEG 3400, 5% (v/v) DMSO, 10% glycerol, 10 mM MgCl2, 10 mM MgSO4) and incubated on ice 
for 10 minutes. The cells were split into 250 µL aliquots and stored at -80 °C until use. 
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2.5.11: Mammalian cell growth and storage 
      TA-g Jurkats cells [77] were grown in RPMI-1640 media (GIBCO) supplemented with 10% 
FBS (GIBCO) and 1% antibiotic-antimycotic (GIBCO). Cells were grown at 37 °C in 5% CO2 to a 
maximum confluency of 1 million cells/mL. Cells were passaged each day and cell count was 
determined using Tryptan blue stain (GIBCO) and a hemocytometer. For storage, approximately 
10 million cells were harvested by spinning at 1000 rpm at 4 °C for 5 minutes and the growth 
medium was removed by aspiration. The cell pellet was re-suspended in 1 mL RPMI -1640 
medium containing 5% glycerol. Cells were transferred into cryovials, which were wrapped in 
styroform and slowly frozen, first at -20 °C overnight, and then transferred to -80°C for a day 
before moving them to liquid nitrogen. 
2.5.12:  DNA transfection 
       Plasmid DNA purified using the QIAgen kit (see section 2.5.8, 20 µg, pBJ5HDAC1-Flag or 
mutants) was separately transiently transfected into 40 X 106 TA-g Jurkat cells by 
electroporation using 4 mM electroporation cuvettes. Briefly, cells were harvested by spinning at 
1000 rpm for 5 minutes at 4 °C. The supernatant was removed by aspiration and the cell pellet 
was resuspended in 20 mL RPMI medium without FBS and phenol red pH indicator (GIBCO) 
followed by spinning and medium removal. The cell pellet was resuspended in 800 µL RPMI 
media (no pH indicator or FBS) and transferred into eppendorf tubes. Plasmid DNA was added, 
mixed, set at room temperature for 10 minutes, and transferred into BTX 4 mM gap 
electroporation cuvettes (Fischer Biotech). Electroporation was carried out using a BTX Electro 
cell manipulator 630. For every 10 X 106 cells in 200 µL media the following settings were used: 
S-250 V, T-500V/capacitance and resistance, C-800 µF and R-129 Ohms. The µF output was 
varied depending on the quantity of cells as follows; 10 X 106 cells: 800 µF, 20 X 106 cells: 1600 
µF, 30 X 106 cells: 2100 µF and 40 X 106: 2800 µF. The pulse length (1/e) was around 35 msec 
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for optimal electroporation and the presence of a frothy precipitate due to dead cells is normal.  
Electroporated cells were set at room temperature for 10 minutes, transferred to 10 mL of warm 
(37 °C) RPMI-1640 (with 10% FBS and 1% antibiotic)  for every 10 X 106 cells and grown for 48 
hours as described in section 2.5.11. The cells were harvested by spinning at 1000 rpm for 5 
minutes at 4 °C and  washed with 1 mL of PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 
1.4 mM KH2PO4  pH 7.3). PBS was removed by spinning at 1000 rpm, for 5 minutes at 4 °C and 
the cells were used immediately or stored at -80 ˚C until use.  
2.5.13: Immunoprecipitation 
      TA-g Jurkat (40 X 106 ) cells expressing HDAC1-FLAG wild type or mutant proteins were 
lysed in  cold Jurkat lysis buffer (50 mM Tris pH 8, 150 mM NaCl, 10% (v/v) glycerol, 0.5 % (v/v) 
Triton X-100) containing 1X protease inhibitor cocktail set V (Calbiochem). Briefly, the cells were 
lysed by pipetting in 0.5 mL of cold JLB buffer for every 20 X106 cells and incubating with 
rotation at 4 °C for 30 minutes. The soluble fraction was separated from cell debris by spinning 
at 15000 rpm for 10 minutes at 4 °C.   Anti-Flag agarose beads (10 µL of bead slurry, Sigma) 
were used to immunoprecipitate HDAC1-Flag wild type or mutant proteins in 1 mL cold TBS 
buffer (50 mM Tris HCL, with 150 mM NaCl, pH 7.4). The beads were prepared by washing 
three times with 0.5 mL TBS followed by spinning at 1000 rpm for 5 minutes at 4 °C, with buffer 
removal in between washes.   Immunoprecipitation was carried out at 4 °C for 2 hours with 
rotation by incubating 400 µL lysates with the washed beads. Immunoprecipitated proteins were 
harvested by spinning at 3200 rpm for 5 minutes at 4 °C. Immunoprecipitates were split in half: 
half was used for gel analysis (section 2.5.14) and the other half for HDAC assays (section 
2.5.15). For gel analysis, FLAG-fusion proteins were eluted from the agarose bead by adding 40 
µL of 0.1M glycine HCl, pH 3.5, and incubating for 5 minutes at 4 °C with gentle shaking. The 
supernatant containing the FLAG-fusion protein was recovered by spinning at 3200 rpm for 5 
minutes at 4 °C. The supernatant was neutralized by transferred into a clean tube containing 
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10µL 0.5 M Tris HCl, pH 7.4, and 1.5 mM NaCl. The eluted protein was used immediately in 
SDS-PAGE experiments (section 2.5.14) 
2.5.14: SDS-PAGE 
      β-mercaptoethanol (1 µL) and 5XSDS loading buffer (10 µL of 50 mM Tris-Cl pH 6.8, 100 
mM dithiothreitol, 2% (w/v) SDS electrophoresis grade, 0.1% bromophenol blue, 10% (v/v) 
glycerol)) was added for every 40 µL immunoprecipated FLAG-fusion proteins. Each solution 
was incubated at room temperature for 5 minutes. The mixtures were heat at 95 °C for 1 minute 
and quickly cooled on ice prior to loading onto the gel. When using lysates, 10 µL lysates was 
added to 10 µL SDS loading buffer with 10% β-mercaptoethanol. The separating layer of the 
SDS-PAGE gel was prepared to contain 10% 37:1 acrylamide/ bisacrylamide (Acros) by mixing 
1 mL 4X Tris/SDS buffer (0.4% SDS, 1.5 M Tris, 0.24 M HCl; pH 8.8), 1.96 mL water, 1 mL 40% 
37:1 acrylamide/bisacrylamide, 40 µL ammonium persulfate and 2 µL 10% TEMED (N, N, N’, 
N’-tetramethylthylenediamine; Acros). The mixture was mixed thoroughly and immediately 
poured into a BioRad mini-Protean tetra cell casting module. The surface of the gel was covered 
with methanol and allowed to polymerize. The stacking layer was prepared by mixing 1.24 mL 
water, 250 µL 40% 37:1 acrylamide/bisacrylamide, 500 µL 4X Tris/SDS buffer (0.4% SDS, 1.5 
M Tris, 0.24 M HCl; pH 6.8), 10 µL of 10% ammonium persulfate and 1 µL TEMED. Methanol 
was removed from the polymerized separating layer and the stacking layer mixture was poured 
followed by the addition of a comb; the layer was allowed to polymerize. The gels were inserted 
into the BioRad (Protean III) gel apparatus, which was filled with SDS running buffer (0.1% 
SDS, 25 mM Tris, 250 mM glycine; pH 8.3). The gel wells were loaded with samples and run at 
200 V for 60 minutes. 
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2.5.15: Western blot and co-immunoprecipitation 
       To probe protein bands with anti-Flag (Sigma), anti-mSin3A (Santa Cruz) or anti-RbAp48 
(Sigma) antibodies, the proteins in the SDS gel were transferred onto a polyvinylidene (PVDF) 
membrane (Millipore Immobilon-P, 0.45 micron).  The membrane was activated for protein 
transfer by soaking in methanol. Both the membrane and gel were assembled between filter 
paper and padding and transferred into the BioRad gel electrophoresis chamber containing an 
ice cooling tray.  The chamber was filled with CAPS/methanol transfer buffer prepared by mixing 
100 mL 10X CAPS (0.1 M CAPS, pH adjusted to 10.5 with 10 M NaOH) and 800 mL distilled 
water. The transfer was run for 1 hour at 90 Volts. The membrane was carefully removed and 
air dried to ensure proteins were bound. The membrane was wet in methanol and blocked 
overnight with 10% low fat dry milk in 10 mL of PBST (PBS with 0.1% Tween). After blocking, 
blocking solution was removed and the membrane was washed three times with 5 mL of PBST 
to remove unbound milk. The membrane was probed with primary antibody (1:10,000 dilution in 
10% low fat dry milk and PBST, containing 0.002% sodium azide preservative) by rocking for 2 
hours.  After 2 hours, the membrane was washed 3 times with 5 mL PBST to remove unbound 
antibody. The membrane was coated with a fluorescently labeled secondary anti-mouse (1: 
5000, Alexa Fluor 647; Life Technologies) or anti-rabbit (1:3000, Alexa Fluor 647; Life 
Technologies) antibody solutions in PBST containing 10% low fat dry milk for 1 hour. The 
antibody solution was removed and the membrane was washed three times with 5 mL PBST to 
remove unbound antibody.  Proteins were visualized using a Typhoon 9210 variable mode 
imager (Amersham Biosciences) by measuring the fluorescence at 670 nM.  
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2.5.16: HDAC activity assay 
      The Fluor de LysTM fluorescence activity assay (Biomol) was used to determine HDAC 
activity. Approximately 20 µg total protein was immunoprecipitated as described in section 
2.5.13 and used in this assay. The bead-bound HDAC immunoprecipitates were  incubated with 
25 µL HDAC assay buffer (50 mM Tris/Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2) and 
25 µL substrate (100 µM; Prod. No. BML-KI104) at 37 ˚C for 45 min with shaking (900 rpm). 
Then, 50 µL 20X developer (Prod. No. BML-KI105) was added and incubated for 5 min at 37 °C. 
The reaction mixture was transferred into a white microplate (Prod. No. BML-K571) and the 
fluorescence signal was measured using the GENios plus plate-reader fluorimeter (Tecan) with 
an excitation wavelength of 360 nm and emission of 465 nm wavelength. The fluorescence 
signal for each mutant was normalized to the wild type (set at 100%) and standard errors from 
at least four independent trials are provided in the appendix (Table A.1 and A.2).  
2.5.17: Acetate competition assay 
      To perform the acetate competition assay, the activity of mutant proteins was determined 
using the Fluor de LysTM kit with some modifications. Immunoprecipitation was done as 
described in section 2.5.13 and then split into 5 equal aliquots. Each aliquot was incubated with 
25 µL HDAC assay buffer containing 0-200 mM sodium acetate (Table A.3-A.9) for 15 minutes 
at 37 ˚C with shaking. The deacetylase activity was determined as described in section 2.5.16. 
The percent deacetylase activity was determined by normalizing the fluorescence signal at each 
concentration to the no acetate control for each mutant (no acetate=100%) and standard errors 
from at least four independent trials are shown in the appendix (Table A.3-A.9).  
 
 
 
 
51 
 
 
Chapter 3 
Introduction 
3.1: Efforts towards the first HDAC1-‘bump hole’ inhibitor pair 
(Portions of the text in this chapter were reprinted or adapted with permission from Weerasighe 
S.V., Wambua M., and Pflum M.K (2010) A Histone dependent screen in Yeast, Bioorg. Med. 
Chem., 18, 7586-7592.) 
      Overexpression of one or more histone deacetylase (HDAC) proteins is observed in many 
cancers (Chapert 1, section 1.5). Unfortunately, it is still unclear which HDAC isoform(s) are 
involved in cancer formation. Understanding the involvement of each HDAC isoform in cancer is 
critical to aid in the design of isoform selective inhibitors. Use of HDAC inhibitors has been 
shown to reduce malignancies but, unfortunately, most HDAC inhibitors interact with all or most 
of the eleven known human isoforms. With FDA approval of the HDAC inhibitors FK-228 and 
suberoylanilide hydroxamic acid (SAHA) for the treatment of cutaneous T-cell lymphomas, the 
discovery of more HDAC inhibitors is a promising area of cancer research. Consequently, 
various HDAC inhibitors are in different phases of clinical trials to treat cancer [62]. 
       HDAC1 is an attractive target for anti-cancer drugs (see chapter 1, section 1.5). HDAC1 
regulates the cell cycle, cellular proliferation and development, key events that can lead to 
cancer development if aberrant. HDAC1-deficient mouse embryonic stem cells deciphered the 
dominant role of HDAC1 in growth, development and cellular proliferation [54].  Specifically, 
deletion of HDAC1 resulted in embryonic lethality at E10.5 in mice, which was attributed to 
severe defects in proliferation and retarded growth [54]. The observed reduction in proliferation 
correlated with the upregulation of cyclin-dependent kinase inhibitors p21 and p27 and an 
overall reduction in deacetylase activity. Importantly, loss of HDAC1 led to induction of HDAC2 
and 3, but both isoforms were unable to compensate for the HDAC1 deletion, suggesting that 
HDAC1 plays a critical role in development and cellular proliferation by regulating cell cycle 
check-point genes. Further, mouse fibroblast cells lacking HDAC1 are anti-proliferative and 
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exhibit G1-cell cycle arrest accompanied by the up-regulation of CDK inhibitors p21 and p53 
[56]. In addition, B-cell development was blocked following HDAC1 deletion, which was 
accompanied by G1-cell cycle arrest and induction of apoptosis. Combined, these studies 
showed that HDAC1 regulates G1-S phase transition in the cell cycle by repressing the 
expression of p21 and p53.  Aberrant cell cycle regulation and proliferation are hallmarks of 
cancer formation, and HDAC1 is thus a potential target for Dace drug design. Currently, no 
HDAC1 selective inhibitor is yet available. 
       To achieve better therapies for cancer treatment, it is important to understand the individual 
functions of each HDAC isoform, which will aid in design of isoform selective HDAC inhibitors. 
As a first step towards this goal, studies in this chapter are focused on HDAC1. Conventional 
genetic strategies have revealed that HDAC1 regulates cell cycle, tissue differentiation and 
development [54, 55].  In addition, the use of mouse knock-out models and siRNA silencing has 
been useful in understanding the individual functions of other HDAC proteins (see section 3.1). 
As an alternative to genetic methods, small molecules offer a temporal, time-dependent, and 
reversible control of gene silencing which is unattainable with genetic methods.  Studies 
outlined here examine the bump-hole approach, a combination of genetic manipulations and 
small molecules incubation, to understand the involvement of HDAC1 in cancer formation.  
Understanding the role of HDAC1 in cancer formation will aid in developing better cancer 
therapies targeting HDACs. 
3.1.2: The utility of a bump-hole pair:  
3.1.2.1: The kinase bump-hole 
       The bump-hole strategy has been used successfully to design allele-specific inhibitors to 
probe kinase signaling (Figure 3.1) [78]. Protein kinases have highly conserved domains, 
making the design of selective highly specific inhibitors very difficult. Chemical biology has 
allowed the design of allele specific kinases to probe kinase signaling for individual kinases. 
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       To create a bump-hole, the kinase protein is mutated to contain a hole and a small 
molecule inhibitor is modified to contain a bump that is complementary to the hole.  A kinase 
bump-hole study focused on two structurally related Src kinases, v-Src and Fyn, which display 
85 % sequence homology in their catalytic domains. A functionally silent threonine to 
isolecucine mutation for the kinase of interest was created in the active site to give rise to a 
unique pocket that could accommodate a bumped adenosine mimic inhibitor [78]. Importantly, 
Figure 25: The kinase bump-hole to probe kinase signaling [78]. A) Kinase catalytic domains 
are highly conserved (red ovals) and therefore the majority of potent kinase inhibitors (red oval) 
would block the activity of closely related kinase and their pathways regulated by kinase activity. 
Gel analysis for phosphorylated proteins shows completed blockage of kinase activity by potent 
inhibitors shown at the bottom.B). Src kinase is engineered to contain a hole that is uniquely 
complementary to a small molecule inhibitor, allowing for selective inhibition of one kinase as 
opposed to all kinases. The panel shows gel analysis for phosphorylated proteins with selective 
blockage of an engineered kinase activity by the modified inhibitor (Pink ovals represent kinase 
substrates; Y and S represent tyrosine and serine respectively). Reproduced with permission 
from Curr. Bio.,1998, 8: 257-266. 
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the ATP mimic inhibited the engineered kinase more potently than the wild type or other non-Src 
family kinases (>100-fold selectivity). Treating NIH3T3 fibroblasts transfected with the 
engineered v-Src kinase with the adenosine-mimic inhibitor blocked tyrosine phosphorylation; 
this phenotype was not observed with the wild type kinase.  To further demonstrate selective 
inhibition of the engineered v-Src kinase variants by a bumped ATP mimic, mammalian cellular 
transformation by the Rous sarcoma virus, which is dependent on v-Src activation, was 
determined. NIH3T3 cells expressing engineered v-Src, but not the wild type v-Src, exhibited flat 
cell morphology upon treatment with the adenosine mimic inhibitor; this morphology is attributed 
to reversal of cellular transformation. Importantly, the engineered Fyn kinase with a mutation at 
a similar position was selectively inhibited by the same adenosine-mimic inhibitor, 
demonstrating that the bump-hole strategy can be extended to other kinase families.  
       Other such bump-hole studies have been done in recent years. For instance, mutation of 
the highly conserved phenylalanine 338 to glycine in the active site of the cyclin-dependent 
kinase Cdc28 (CDK1) creates a unique ATP-mimic inhibitor binding pocket in [79]. The smaller 
glycine residue acts as a gate keeper to allow for bulkier ATP analogs to access the active site 
and sensitizes Cdc28 to specific inhibitors. The allele-sensitive Cdc28 was used to understand 
the biology of budding yeast. Specifically, inhibiting the mutant Cdc28, but not the wild type 
enzyme, in vivo caused pre-mitotic cell cycle arrest and thereby facilitated a functional 
characterization of this kinase [79].  A different study focused on the Toxoplasma gondii 
calcium-dependent protein kinase 1 (TgCDPK1) [80]. Unlike other protein kinases in T. gondii, 
the presence of a glycine residue at the gate-keeper position renders TgCDPK1 sensitive to 
pyrazolopyrimidine-derived inhibitors and mutating the glycine to a methionine residue leads to 
insensitivity [80].  Specific inhibition of TgCDPK1 revealed that TgCDPK1 controls calcium-
dependent secretion of specialized organelles, the micronemes, which blocks parasite motility, 
host-cell invasion and egress [80]. These observations were recapitulated using conditional 
knock-out models as well as expression of a resistant mutant kinase or other T. gondii protein 
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kinases [80]. A recent development was reported in 2012 [81]. In this study, the methionine 
residue at the gatekeeper position of calcium-dependent protein kinase 3 (TgCDPK3) was 
mutated to glycine and thereby rendered sensitive to a pyrazolopyrimidine-derivative inhibitor 
(PPI). Inhibiting the allele-specific TgCDPK3 with PPI derivatives demonstrated that TgCDP3 is 
essential for parasite egress but not host invasion or motility [81]. These combined studies 
demonstrate the successful use of allele-specific kinases along with enlarged inhibitor 
compounds with increased potencies for functional characterization of closely related protein 
kinases in T. gondii. 
3.1.2.2: HDAC1-inhibitor bump-hole 
       Allele-specific kinase inhibitor pairs have been used to understand kinase signaling and 
biological relevance (section 3.1.2.1). Similar to kinases, an allele specific HDAC1-inhibitor pair 
would be useful for understanding HDAC1 biology.  Importantly, the bump-hole is a great 
alternative to the development of isoform selective HDAC inhibitors, in order to explore HDAC1 
biology. 
       A functional characterization of the role of HDAC1 in cancer can be conducted using the 
bump-hole strategy in cell based assays (Figure 3.2). Our proposition is that HDAC inhibitors 
(HDACi) can be modified to contain a steric bump which is accommodated by a mutant HDAC1 
with a complementary hole (Figure 3.2A). Importantly, the modified HDACi must be excluded 
from binding the wild type HDAC1 (Figure 3.2B). The HDAC1-inhibitor bump-hole pair can be 
used to study the expression profiles of cancer related genes influenced by HDAC1.  
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       The HDAC1-inhibitor bump-hole pair is summarized in Figure 3.3. The wild type HDAC1 is 
knocked down using siRNA (Figure 3.3B). The active HDAC1 mutant containing a ‘hole’ is 
expressed (Figure 3.3C) at the same time that the wild type HDAC1 is knocked down by siRNA. 
A small molecule inhibitor analogue is used to inhibit the mutant but not the other HDAC 
isoforms (Figure 3.3D).  The expression profile of cancer related genes influenced by HDAC1 
alone but not the other HDAC isoforms is determined by comparing the results from panels C 
and D. Further, inhibiting all HDAC isoforms can be done using a pan-HDAC inhibitor (Figure 
3.3E or F) and comparative studies for expression profiles gives the cancer related genes 
influenced by all the other HDAC isoforms but not HDAC1.  
 
 
 
 
Figure 26: A cartoon showing the rationale of the bump-hole approach. (A) Wild-type 
HDAC1 is mutated to contain a hole.  A small molecule inhibitor is modified to contain a bump. 
The bumped inhibitor fits into the hole of the mutant but not the wild type. B) In a cellular 
context, the modified inhibitor analogue inhibits the mutant HDAC1 but not the wild type or the 
other HDAC isoforms. 
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3.1.2.3: Approaches to obtain an HDAC1-inhibitor bump-hole pair 
       Unfortunately, the creation of active HDAC1 mutants for use in the bump-hole has been 
challenging (Chapter 2). With over 80 HDAC1 mutants characterized so far in the Pflum lab, 
only the E98A mutant was catalytically active, making it challenging to proceed with the bump-
hole project (Chapter 2, figure 2.7). As an alternative, we envisioned creating combinations of 
several point mutations, which might restore catalytic activity. This approach is only feasible in 
the more tractable yeast system, which is easier to manipulate. HDAC1 is homologous to the 
yeast Rpd3 protein and therefore active mutations in Rpd3 are often conserved in HDAC1. Our 
second approach for creating a bump-hole pair was to screen the active HDAC1E98A protein 
against libraries of SAHA analog compounds produced in the Pflum lab. Both of these strategies 
are discussed in this chapter.  
 
Figure 27: Dissecting the individual functions of HDAC1 using the bump-hole strategy.  
siRNA is used to knock-out HDAC1 (B). The engineered HDAC1 mutant is expressed (C). 
Cells are treated with a bumped-inhibitor analogue which selectively inhibits the mutant 
HDAC1 but not the other HDAC isoforms (D). Pan-HDAC inhibitor is introduced to inhibit all 
the HDACs (E and F). 
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3.2: Results 
3.2.1: Development of an HDAC dependent yeast gene reporter screen  
       Rpd3, the yeast histone deacetylase shares 60% sequence identity with its human HDAC1 
homologs and is a component of the Sin3 corepressor complex [82]. However, unlike HDAC1, 
which regulates growth, development, cell cycle and proliferation, the Rpd3-Sin3 repressor 
complex negatively regulates genes involved in potassium transport, meiosis, phospholipid 
metabolism, phosphate metabolism and cell-type specificity [82]. The high sequence similarity 
between Rpd3 and class I HDACs makes Rpd3 an ideal model to study class 1 proteins in the 
more tractable yeast system. Therefore, it is probable that active mutants obtained in Rpd3 will 
be transferable to human HDAC1. A major challenge, however, is to have a functional screen 
for selecting active mutants from a large mutant library. This issue necessitated the 
development of a yeast reporter screen dependent on Rpd3 activity. 
       A high throughput screen capable of testing a library of Rpd3 mutants for activity is ideal. 
The current fluorimetric assay used in chapter 2 is sensitive and is the most widely used in the 
field. The assay is dependent on fluorophore-labeled peptide substrate and has been widely 
used for mutant and inhibitor studies. In addition, several other assays developed in the past 
have relied on radio-labeled acetylated histones or peptide substrates [7]. Unfortunately, the 
HDAC is usually sourced from HeLa nuclear extracts and is therefore disadvantageous in 
inhibitor screens because the inhibition profile is a reflection of the overall HDAC activity and 
cannot be attributed to a specific HDAC isoform.  Efforts to purify individual isoforms for 
selectivity studies are hindered by the fact that bacterially expressed HDACs are inactive, 
presumably due to the lack of associated proteins, which are needed for catalytic activity. As an 
alternative, baculovirus-expressed HDAC sources, which have shown 70% reduction in 
enzymatic activities, have also has been explored but this loss in deacetylase activity limits their 
use. In addition, these assays are cost prohibitive and would therefore not be ideal for a high 
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throughput, library screening. The development of a high throughput cost effective screening 
assay will be ideal for identification of active mutants and inhibitor screen. Further, the histone 
deacetylase screen developed in Rpd3 is dependent on native substrates unlike the commercial 
kits.    
3.2.1.1: Design of a yeast gene reporter screen 
       The Rpd3 dependent yeast gene reporter screen utilizes the LACZ gene product β-
galactosidase, which cleaves 5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal), giving 
a blue color, or 2-Nitrophenyl β-D-galactopyranoside (ONPG), giving a yellow color (Figure 
3.4A). These color changes can be monitored to assess HDAC activity. Rpd3 is expressed as a 
LexA fusion protein; LexA recruits Rpd3 to the LexA DNA binding promoter region upstream of 
the LACZ gene. The yeast FT5ΔRpd3 strain, with a deletion of the endogenous Rpd3, is 
transformed with reporter plasmid and the Rpd3 expression construct. Transformation of the 
LACZ reporter alone gives basal LACZ expression under a constitutively active promoter and 
results into a colored cell (Figure 3.4A). Expression of Rpd3-LexA together with the reporter 
results in recruitment of Rpd3 to the LexA DNA binding region in the promoter region. Rpd3 will 
deacetylate nucleosomal DNA turning off LACZ gene transcription. Lack of β-galactosidase 
activity then yields a white cell (Figure 3.4.B).  A catalytically inactive mutation in Rpd3 or 
inhibition of the wild type Rpd3 leaves DNA acetylated, LACZ gene transcription is turned on 
and the cells are colored (Figure 3.4C). The LACZ gene reporter can screen Rpd3 mutants for 
activity or inhibitor selectivity. 
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Figure 28: Schematic diagram of yeast based LACZ gene reporter screen. (A) When the 
LACZ reporter is transformed alone, the LACZ gene under the control of a constitutively active 
promoter, expresses β-galactosidase (β-gal) which hydrolyzes the 5-Bromo-4-chloro-3-indolyl-
β-D-galactopyranoside substrate (X-Gal), resulting a blue color, or the 2-Nitrophenyl β-D-
galactopyranoside substrate (ONPG), resulting in a yellow color. The color changes can be 
monitored to assess the HDAC activity. (B) When the catalytically active Rpd3 LexA fusion is 
expressed and recruited to the reporter, the nucleosomal DNA will be deacetylated and 
inaccessible to the transcription machinery, causing LACZ gene transcription to be turned off 
and the cells to be white. (C) A catalytically inactive Rpd3 mutant fails to inhibit LACZ 
expression and results in blue and yellow cells. Inhibiting active Rpd3 mutants or wild type 
with a small molecule will give similar results.   
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3.2.1.2: Validation of the Rpd3-dependent screen using a qualitative X-Gal agar format 
       To determine if the yeast screen is suitable for mutant and inhibitor screening, the assay 
was developed and optimized. The LACZ reporter plasmid, pJK1621 (obtained from Prof. 
Struhl), was transformed into the FT5 Δrpd3::HIS3 yeast strain (wherein the endogenous rpd3 is 
deleted) with or without the Rpd3-LexA fusion plasmid (cloned in our lab, see section 3.5.2) [69]. 
The β-galactosidase activity was monitored using X-Gal. The X-Gal assay is a qualitative agar 
layout that allows for an initial validation of the screen. The LACZ reporter alone strain showed 
basal β-galactosidase activity and a resultant blue colored yeast cell (Figure 3.5A). 
Transforming the LACZ reporter together with Rpd3 resulted in low β-galactosidase and a white 
colored cell (Figure 3.5C), suggesting that Rpd3 represses LACZ gene expression.  As 
expected, the catalytically inactive Rpd3H150A151A mutant showed low β-galactosidase levels 
that were comparable to the reporter alone and gave a blue colored cell (Figure 3.5 D). 
Inhibiting Rpd3 with trichostatin A (TSA) resulted in high levels of β-galactosidase and a blue 
color as expected (Figure 3.5F).  Endogenous HDAC activity with the LACZ reporter alone is 
negligible as TSA treatment gave similar β-galactosidase activities (Figure 3.5B). The solid X-
Gal screen is therefore ideal for mutant and inhibitor screens.  
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3.2.1.3: The LACZ gene reporter assay can be quantified 
       A quantification of Rpd3 dependent repression of β-galactosidase activity was further 
determined using ONPG as a substrate. The liquid format makes it possible to quantify the 
amount of Rpd3 deacetylase activity by measuring the absorbance of ONPG hydrolysis product 
at 420 nm. The LACZ reporter plasmid alone gave high levels (2.4-fold compared to wild type 
which was normalized to 1) of β-galactosidase and is consisted with X-Gal results (Figure 3.6, 
column 1 reflecting basal LACZ expression levels from a constitutive promoter. Rpd3-LexA, 
together with the LACZ reporter resulted in loss in β-galactosidase activity, suggesting that 
Rpd3 repressed LACZ expression (Figure 3.6, column 3). However, this suppression was 
reversed by TSA treatment and resulted in 2.5-fold increase in β-galactosidase activity.  The 
inactive Rpd3 H150AH151A mutant was unable to suppress LACZ expression and resulted in a 
2.4-fold increase in β-galactosidase activity (Figure 3.6, column 5). Importantly, the LACZ 
reporter alone gave similar β-galactosidase activity with and without TSA, suggesting that 
endogenous HDAC activity is negligible, as previously observed with the X-GAL assay (Figure 
Figure 29: The Rpd3-dependent gene reporter screen (data obtained by Sujith Weerasighe) 
[83]. LACZ reporter plasmid, pJK1621, was transformed with or without wild type Rpd3 or 
catalytically inactive Rpd3 mutant as LexA-FLAG fusions, into FT5 Δrpd3::HIS yeast strain. 
Transformed cells were grown with or without TSA for 48 h in 96 well format and were overlaid with 
X-Gal substrate. The β-galactosidase activity was observed qualitatively by blue color formation 
after 3h of X-Gal incubation. Columns represent (A) LacZ reporter alone, (B) LacZ reporter + TSA 
100 µM, (C) LacZ reporter + Wild type Rpd3-LexA, (D) LacZ reporter + Rpd3-LexA mutant, (E) 
LacZ reporter + wt Rpd3-LexA +100 µM TSA and (F) LacZ reporter + Rpd3-LexA mutant + 100 µM 
TSA. The experiments were carried out in triplicate (rows 1, 2 and 3).  Reproduced with permission 
from Bioorg. & Med. Chem., 2010, 18, 7586-7592. 
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3.6 lane B). The combined results indicate that both the qualitative X-Gal and quantitative 
ONPG assays are dependent on the activity of Rpd3-LexA, making the yeast screen ideal for 
identifying active mutants as well as inhibitor screen.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Quantitative inhibition of Rpd3 activity; data obtained by Sujith Weerasighe 
[83]. LacZ reporter plasmid, pJK1621, was transformed with or without wild type Rpd3 or 
catalytically inactive Rpd3 mutant as LexA-FLAG fusions into FT5 Δrpd3::HIS yeast strain. 
Transformed cells were grown with or without TSA for 6h at 30 °C and β-galactosidase activity 
was measured quantitatively using ONPG and absorbance at OD420. Relative fold change in β-
galactosidase activity was calculated with respect to wild type Rpd3 and mean of three trials is 
shown with standard error (as error bars). Relative fold changes observed in each trial are 
summarized in Appendix B (Table B.1). Reproduced with permission from Biorg. & Med. Chem., 
2010, 18, 7586-7592.  
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3.2.1.4: Screening yeast libraries for active mutants 
       The LACZ gene reporter assay was used to screen a 15,000 member library (see 
experimental section 3.5.1 and 3.5.2) previously generated by Sujith Weerasighe (unpublished 
work). The amino acids F214, F215, and L281 positions were mutated to create this Rpd3 
library. These amino acids are located near the solvent exposed region of the enzyme’s active 
site and their contributions to the catalytic activity of Rpd3 has never been reported (F214, F215 
and L281, are similar to F204, F505 and F271 in HDAC1 respectively and are located further 
from the active site (Chapter 2, figure 2.6). We envisioned that random mutagenesis would 
create a combination of mutants that could be active; loss of activity as a result of a mutation of 
one amino acid could be compensated for by another amino acid in the same mutant, therefore 
increasing the chances of creating an active mutant for the bump-hole approach. In order to 
screen the 15,000 mutants for activity using the yeast gene reporter assay as described in 
section 3.2.1.1, mutants were transformed into the FT5ΔRpd3::HIS strain cell line together with 
the LACZ gene reporter plasmid, pJK1621. Transformed yeast cells were subjected to blue-
white screening as discussed in section 3.5.6. A representative result of the X-Gal blue-white 
screen is shown in Fig. 3.7 (white colonies are shown by arrows).  The expectation was that 
cells containing an active Rpd3 mutant would repress β-gal expression and color change. It was 
necessary to do an initial selection screen to identify possible hits for further evaluation using 
the quantitative ONPG assay and fluorescence assay. One hundred white colonies were picked 
to move forward to further screening. 
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3.2.1.5: Quantification of β-galactosidase activity for white mutants identified in X-Gal 
screen 
       The ONPG screen allows for quantification of deacetylase activity for white colonies and is 
also a secondary confirmatory assay of the quantitative X-Gal plate assay. To confirm the 
deacetylase activities of colonies from the blue-white screen using X-Gal (Section 3.2.1.4), 
colonies were retrieved from the agar, re-grown for 2 days in liquid medium and the ONPG 
assay was applied as described in experimental section 3.5.7. A representative screen for ten 
white colonies (out of the hundred selected) is shown in figure 3.8. The wild type Rpd3 
repressed β-galactosidase expression and showed low levels of activity as expected (Figure 
3.8, column 1, positive control). The inactive Rpd3H150AH151A double mutant was unable to 
repress LACZ expression and resulted into a 4.5-fold increase in β-galactosisade activity 
(column 2, negative control). Out of the ten mutants screened in this representative assay, 
mutants 3 and 7 showed low β-galactosidase activities (Figure 3.8, columns 3 and 10). The rest 
of the mutants showed high β-galactosidase activities (Figures 3.8, columns 1, 2 and 4-9) 
Figure 31: LacZ gene reporter screen for active mutants (X-gal overlay assay; Blue-white 
screen). Rpd3 mutant expression plasmids were transformed into the FT5ΔRpd3::HIS strain 
cell line. Yeast cells were grown for 3 days and overlaid with X-Gal solution and then incubated 
for 2 hours. Development of blue color was monitored visually. The arrows show white mutants 
that are thought to be ‘active mutants’ from this screen. 
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suggesting that these mutants do not repress LACZ expression.   In total, the ONPG assay 
validated 60 colonies which were screened for activity using a fluorimetric assay (Section 
3.2.1.6). 
 
 
 
 
 
 
 
 
 
 
3.2.1.6: HDAC assay for identified mutants 
       In order to validate the activity of the 60 mutants form the ONPG screen, the commercially 
available kit, Fluor-de-Lys (Biomol), was used to confirm HDAC activity (Appendix B.3). A 
representative set of results is shown in Figure 3.9. The wild type Rpd3 has high deacetylase 
activities (set to 100%) whereas the mutant Rpd3H150AH151A mutant has low deacetylase 
Figure 32: LacZ gene reporter assay screen for active mutants (ONPG assay). LacZ 
reporter plasmid, pJK1621, was transformed with wild type Rpd3 or a catalytically inactive Rpd3 
mutant or the Rpd3 library plasmid DNA as LexA-FLAG fusions into the FT5 Δrpd3::HIS yeast 
strain. Transformed cell were grown overnight at 30 °C. β-galactosidase activity was measured 
quantitatively. Relative fold change in β-galactosidase activity was calculated with respect to 
wild type Rpd3 and the mean of two trials is shown (no error bars). Mutants 3 and 10 are 
thought to be active mutants. While data from a single trial is shown here, the relative fold 
change observed in two independent trials is summarized in Appendix B (Table B.2). 
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levels (20%) compared to wild type (Figure 3.9). Of the five mutants tested, mutants 3 and 6 
maintained high deacetylase activities at 93% and 85% respectively (Figure 3.9, columns 3 and 
6). The three other mutants had low deacetylase levels (10-30%) comparable to the 
Rpd3H150AH151A control (Figure 3.9, columns 4, 5 and 7). Using the HDAC assay, 19 of the 
60 mutants were confirmed as active mutants; these were sequenced to determine the 
presence and identification of any mutations. 
 
 
 
 
 
 
 
 
 
 
 
       The sequence data for all the isolated plasmids showed wild type sequence (Figure 3.10). 
The data from this project reinforces the fact that it is very difficult to create active Rpd3 mutants 
and is consistent with our observations with human HDAC1 (Chapter 3). As an alternative to 
identifying a HDAC1-inhibitor bump hole pair, our attention turned to screening the only active 
mutant for HDAC1, E98A against SAHA analogs available in the Pflum lab. 
Figure 33: Representative results from an HDAC assay of active mutants identified using 
the LacZ gene reporter screen. Rpd3 wild-type, Rpd3 H150A151A mutants or the validated 
mutant(s) were expressed as FLAG-tagged fusion proteins and were immunoprecipitated with 
anti-FLAG-agarose resin. The immunoprecipitated protein were used in fluorescence HDAC 
assays .The percent activity is compared with that of the wild-type protein (100%). The 
deacetylase activities for each trial are summarized in Appendix B (Table B.3). 
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3.3: Development of a high throughput ELISA assay to screen small molecules for bump-
hole experiments 
       To screen a library of small molecules for selectivity against the active HDAC1E98A 
protein, it was necessary to develop an assay that is high throughput and inexpensive. ELISAs 
are luminescence-based assays that utilize luciferin, which is converted to oxyluciferin (Figure 
3.11). Briefly, secondary antibody coated plates (G Bioscience) were incubated with a 
monoclonal anti-FLAG antibody. Next, lysates from HDAC1-FLAG or the mutant fusion protein 
were added and bound to the FLAG epitope. The deacetylase activities of the bound wild type 
or mutant protein were monitored by release of luciferin, which was converted to oxyluciferin by 
luciferase in the presence of Mg2+ and ATP. The amount of luminescence is directly proportional 
to deacetylase activity. Active mutant(s) exhibit high luminescence activity, comparable to wild 
type. A small molecule inhibitor of HDAC1 activity should abolish luminescence. Using this 
assay, we set out to screen E98A against all SAHA analogs produced in our lab. 
 
 
Figure 34: A representative chromatogram of an active mutant. The chromatogram shows 
the sequence data obtained for one mutant confirmed from the HDAC flourimetric assay. The 
other 19 mutants also had the wild type sequence.  The three amino acid residues are boxed 
off and shown on top of each chromatogram. 
69 
 
 
 
 
 
 
 
 
 
 
 
3.3.1: ELISA assay is ideal for screening HDAC inhibitors 
       To assess whether the plate-based ELISA assay was suitable for screening HDAC 
inhibitors against E98A for a bump-hole design, the HDAC inhibitor trichostatin A (TSA) was 
tested and the amount of deacetylase activity was measured. In addition; the deacetylase 
activities of the catalytically active E98A mutant in the presence and absence of TSA were also 
determined. Importantly, the deacetylase activity of the negative control (no protein) was 
comparable to the assays with HDAC1 and TSA. Wild type HDAC1 and the active E98A mutant 
showed high deacetylase activities at 100 and 115%, respectively (Figure 3.12, columns 3 and 
4). Importantly, inhibiting HDAC1 or E98A with TSA reduced deacetylase activities to 25% and 
28% respectively (Figure 3.12, columns 5 and 6). The no protein control and H141A had low 
deacetylase activities even without TSA (Figure 3.12, columns 1 and 2). These combined 
Figure 35: Plate based ELISA assay to determine the deacetylase activity of wild type or 
active HDAC1 mutant(s).  Secondary antibody coated plates (G bioscience) were incubated 
with α-flag antibodies and lysates from HDAC1-FLAG or mutant protein(s). The deacetylase 
activity of the HDAC1 or the mutant bound to the plate cleaves the acetyl group from the luciferin 
peptide substrate. The developer contains trypsin, which cleaves the peptide bond between 
luciferin and the lysine of the deacetylated product. Luciferin is converted to oxyluciferin (star 
with GLOW) by luciferase in the presence of Mg2+ and ATP. Upon deacetylation, luciferin was 
released and is converted to oxyluciferin. The amount of luminescence is directly proportional to 
the deacetylase activity of each tested protein. 
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results show that the ELISA assay is suitable for screening small molecules against HDAC1 and 
the E98A mutant for selectivity in order to create a bump-hole pair.   
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.2: Screening SAHA- analogues to create the first HDAC1-inhibitor bump-hole pair 
       C-2, C-3, C-6, and N-SAHA analogues have half-maximal inhibition activities in the 
micromolar range against HeLa nuclear extracts. The ideal bump-hole inhibitor would have poor 
activity against wild type proteins [84-86]. These SAHA analogues contain steric bumps and 
therefore have the potential to inhibit mutant but not wild type HDACs. Each SAHA analog was 
screened against HDAC1E98A using the ELISA assay. 
Figure 36: Deacetylase activities of wild type or mutant proteins were inhibited by TSA.  
HDAC1 wild-type or mutants were expressed as FLAG-tagged fusion proteins and were captured 
on α-FLAG bound to secondary antibody coated plates. The deacetylase activity of 
immunoprecipitated protein was determined using the luminescence assay. The percent activity 
is compared with that of the wild-type protein (100%) with standard errors shown. The 
deacetylase activities for each trial are summarized in Appendix B (Table B.4). 
 
71 
 
 
3.3.2.1 Screening C-2 SAHA analogs 
 
 
 
       C-2-SAHA analogues, previously synthesized in the Pflum lab have IC50 values of 75-450 
µM against HeLa lysates (Table 3.1) [84]. Attaching a bulky substituent at the C-2 position leads 
to a dramatic decrease in potency compared to the parent SAHA inhibitor (500-5000 fold 
decrease), making this class of bumped SAHA analogues potential candidates.   
 
 
 
 
 
 
 
 
aValues are the means of three experiments with standard error given in parentheses [84].  
Structures of SAHA analogs are summarized in Appendix C, Table C.1. 
 
       The ELISA assay was used to test the C-2 SAHA analogs mutant for selectivity towards the 
active HDAC1E98A. We hypothesized that the glutamic acid at position 98 in HDAC1 acts as 
gate keeper and a mutation to alanine would allow for bulkier substituents to access the active 
site, as had been observed with kinases [79-81]. Because all C-2 SAHA analogs display half-
maximal inhibitions in the micromolar range (Table 3.1), all analogues were included in an initial 
single screen to identify compounds for further evaluation. 
         As shown in Table 3.1, most C-2-SAHA analogs inhibited the wild type and the active 
HDAC1E98A mutant to the same extent, with the exception of the C-2-pentyl and C-2-hexyl 
Table  3.1: HDAC inhibition by SAHA C-2 analogs 
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SAHA analogs. Interestingly, the C-2-hexyl and pentyl SAHA analogs, with the longest 
substituents, were more potent against the E98A mutant (39% and 55% remaining activity, 
respectively) compared to HDAC1 (95% and 98% activity, respectively). These data suggest 
that the E98A mutant could be allowing the bulkier pentyl and hexyl substituents to enter the 
active site and possibly gain access to the 14 Å channel. The observed selectivity of C-2-hexyl 
and C-2-pentyl SAHA for E98A encouraged us to determine the IC50 values for the two SAHA 
analogs 
 
.aValues were determined from a single screen. 
       An ideal HDAC1 bump-hole pair, with the active E98A mutant and a SAHA analog, should 
demonstrate at least one hundred-fold lower IC50 compared to wild type [78]. To determine 
whether C-2-pentyl or C-2-hexyl SAHA showed this level of selectivity towards the E98A mutant 
over wild type, the half-maximal inhibition of analog was determined using the ELISA assay as 
described (Figure 3.11). C-2-hexyl-SAHA had an IC50 value of 34.5 µM and 171 µM against the 
E98A and HDAC1, respectively (Figure 3.13). The half-maximal inhibition of the C-2-pentyl-
SAHA against HDAC1 and E98A was 18.9 µM and 100 µM, respectively (Figure 3.14). These 
observed 5-fold changes in IC50 values are not significant enough for a bump-hole pair.   
 
 
 
 
Table 2.2: Percent deacetylase activities for wild type or HDAC1E98A treated with C-2-
SAHA analogs at indicated concentrations 
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Figure 37: Deacetylase inhibitory activities of C-2-hexyl-SAHA. HDAC inhibitory 
activities of the C-2hexyl-SAHA measured against HDAC1 (circles) or E98A (open 
squares). Mean percentage deacetylase activities of three independent trials with standard 
errors are shown (as error bars). Deacetylase activities of individual trials are summarized 
in Tables B.4 and B.6 in appendix B. 
 
Figure 38: Deacetylase inhibitory activities of C-2-pentyl-SAHA. HDAC inhibitory 
activities of the C-2-pentyl-SAHA measured against HDAC1 (circles) or E98A (open 
squares). Mean percentage deacetylase activities of three independent trials with standard 
errors are shown (as error bars). Deacetylase activities of individual trials are summarized in 
Tables B.7 and B.8 in appendix B. 
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3.3.2.2:  Screening SAHA analogues functionalized at C-3 position 
 
 
 
       The observation that some C-2 SAHA analogs show selectivity for the active E98A mutant 
encouraged us to screen a C-3 library of analogs previously synthesized by Sun Ea Choi (see 
Appendix C, Table 3.2 for structures) [86]. Unlike the C-2 library, C-3 SAHA analogs display 
half-maximal inhibition in the lower micromolar range (Table 3.3). The decreased (4-2000 fold-
decrease) in potency for this class of compounds compared to the C-2 analogs suggests that 
the C-3 position is less constrained and can be explored for designing isoform selective 
inhibitors. Similar to C-2 analogs, we hypothesized that bulkier substituents at C-3 would gain 
access to the active site in the E98A mutant compared to the wild type. An initial screen was 
done using the ELISA assay to identify hits for further studies (Table 3.2).   
                           
                           
 
 
                  
 
aValues are the means of three experiments with standard error given in parentheses. 
       C3-SAHA analogs inhibited both the wild type and the active E98A mutant to the same 
extent (Table 3.4). Specifically, the bulkier substituent C-3-butyl and C-3-phenyl-SAHA analogs 
abolished deacetylase activites for both the wild type and E98A enzymes to similar levels (50% 
versus ~60% respectively). Interestingly, both the C-3-vinyl and C-3-ethyl-SAHA analogs 
demonstrated a two-fold selectivity for E98A over in HDAC1. Collectively, our results indicate 
that the C-3 library is equally as potent for the E98A mutant and the wild type. We speculate 
Table 3.3: HDAC inhibition by SAHA C-3 analogs 
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that, unlike the C-2-library which showed more preference for the mutant E98A, the C-3-SAHA 
analogs are unable to access the 14 Å channel as might be the case with the C-2-library. With 
these results, the analogs were not studied for IC50.  
 
 
 
 
aValues were determined from a single screen. 
3.3.2.3:  Screening SAHA analogues functionalized at the hydroxamic acid nitrogen. 
 
 
 
       Our results from the C-2 library screen encouraged us to screen SAHA analogs 
functionalized at the metal binding moiety. Our hypothesis was that since a long carbon chain in 
the C-2 library shows preference for the mutants, possibly by accessing the 14 Å channel, the 
N-library could also access this channel easily since the metal binding moiety is next to the 
channel. Our previous results from mutagenesis studies indicated that residues in the 14 Å 
channel are critical for maintaining HDAC1 activity (Chapter 2). Further, selective HDAC1 
inhibitors targeting this channel have been created. We thus wondered if E98A would bind N-
SAHA analogs (see Appendix C, Table 3.2 for a summary of N-SAHA analogs) with the ability to 
access the 14 Å channel to allow us to selectively inhibit the mutant over the wild type to 
generate a bump-hole pair.   
 
 
 
Table 3.4: Percent deacetylase activities for wild type or HDAC1E98A treated with 
C-3-SAHA analogs at indicated concentrations. 
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aValues are the means of three experiments with standard error given in parentheses.* indicates 
IC50 value could not be determined due to solubility problems. 
 
       Using the ELISA assay, we screened N-SAHA analogs (all synthesized by Dr. Anton) for 
ideal candidates for the bump-hole. The HDAC inhibitory activities of the SAHA analogs were 
measured using the ELISA chemiluminescence activity assay against the HDAC1 and 
thHDAC1E98A mutant.  A single screen was used to determine the potency of the small 
molecules (Table 3.6). 
aValues were determined from a single screen. 
       With the exception of N-methyl-SAHA, all N-SAHA analogs equally inhibited the mutant 
E98A and the wild type in the micromolar range (Table 3.6). The half-maximal inhibition for N-
benzyl and N-homobenzyl substituents against the mutant and the wild type were 80 µM and 
150 µM, respectively. N-biphenyl-SAHA was two-fold more selective for the mutant (29% 
remaining activity) compared to the wild type (57% remaining activity). N-pentyl-SAHA, whose 
IC50 against HeLa lysates showed more potency against the wild type and the mutant to the 
same extent. Interestingly, the smallest N-SAHA analog, N-methyl-SAHA, was more selective 
Table 3.5: HDAC inhibition by N-SAHA analogs 
 
Table 3.6: Percent deacetylase activities for wild type or HDAC1E98A treated with N-
SAHA analogs at indicated concentrations. 
 
77 
 
 
for the mutant over the wild type (39% versus 117% remaining activity). The methyl group could 
form favorable interactions with amino acids in the 14 Å cavity. With these promising results, we 
further characterized the N-methyl-SAHA analog by determining the IC50 value. N-methyl-SAHA 
had an IC50 value of 2.5 µM and 11.5 µM against E98A and HDAC1 respectively (Figure 3.15). 
This represents a 5-fold selectivity for the mutant over the wild type, which is insufficient bump-
hole.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39: Deacetylase inhibitory activities of N-methyl-SAHA. HDAC inhibitory activities 
of N-methylSAHA measured against HDAC1 (circles) or E98A (open squares). Mean 
percentage deacetylase activities of three independent trials with standard error are shown (as 
error bars). Deacetylase activities of individual trials are summarized in Tables B.9 and B.10 in 
appendix B. 
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3.4: Discussion 
        Identification of isoform selective HDAC inhibitors is necessary to provide better cancer 
therapies. Understanding the individual functions of each HDAC isoform in cancer formation will 
facilitate targeted drug design. The crucial function of HDAC1 in growth, development, 
proliferation, cell cycle progression and cancer formation makes it an ideal target for inhibitor 
design. To understand the involvement of HDAC1 in cancer formation, the bump-hole approach 
proposed in this thesis offers great promise if actualized. Unlike, genetic methods, use of small 
molecules to inhibit the active site of HDAC1 would allow for temporal, dose-dependent and 
reversible control of cancer-related genes influenced by HDAC1. In addition, inhibiting the active 
site should not interfere with HDAC1 binding to associated proteins, otherwise needed for 
activity, with genetic methods, involving HDAC1 deletions do not offer this advantage.  
       Towards this goal, we used two different approaches to create the first HDAC1 inhibitor 
bump-hole pair that would have allowed the characterization of roles the involvement of HDAC1 
in cancer formation. The bump-hole relies on successful creation of a t mutation in the HDAC1 
active site, which has been unattainable for the last 10 years in the Pflum lab (Chapter 2). With 
only one active mutant in hand (HDAC1E98A), we first explored the creation of active mutants 
using the yeast Rpd3 deacetelyase, as an HDAC1 model. The second part of our effort to 
create an HDAC1 inhibitor bump-hole pair focused on screening this one active mutant for 
selectivity towards a library of small molecule SAHA analogs synthesized in the Pflum lab.  
       To identify active mutants from a library of Rpd3 mutants, a functional gene reporter screen 
dependent on Rpd3 deacetylase activity was developed and optimized. The assay can be 
performed both qualitatively and quantitatively. The qualitative X-Gal screen allows for 
identification of possible active mutants by observing blue colored colonies. The inactive Rpd3 
would be unable to repress β-gal expression to give a blue color compared to the wild type, 
which would yield white colonies (Figure 3.4) demonstrating that active mutants can be 
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distinguished from inactive mutants by observing color formation. Quantification of the 
deacetylase activity for inactive Rpd3 mutants gave a 2.4-fold increase in β-galactosidase 
activity (Figure 3.6). These results indicated that the gene reporter assay is suitable for 
screening Rpd3 library for active mutants. 
       We screened a library of 15,000 Rpd3 mutants for activity using the LACZ gene reporter 
assay and validated the activity of selected plasmids using the commercially available 
fluorescence assay. We envisioned that cells containing active Rpd3 would be transferable to 
HDAC1, for use as a bump-hole. Active Rpd3 mutants showed a white color comparable to wild 
type (Figure 3.7). The quantified Rpd3 activities for these positive hits with the OPNG assay 
gave 2-23–fold increases in β-galactosidase activity (Figure 3.8). Further, these deacetylase 
activities were confirmed using the commercially available fluorescence assay (Figure 3.9). 
Upon sequencing however, we did not identify any possible mutants (Figure 3.10); only wild 
type Rpd3 was observed. 
       With these results, we turned to the active HDAC1E98A mutant and screened 
functionalized SAHA analogs for selectivity to create a HDAC1 inhibitor bump-hole pair. This 
approach necessitated the development of a high throughput ELISA assay (Figure 3.11). 
Consistent with previous results (Chapter 2), the E98A mutant and wild type displayed high 
deacetylase levels, which were abolished by the HDAC inhibitor trichostatin A (Figure 3.12). 
These results demonstrate that the ELISA assay is suitable for screening SAHA analogs for 
selectivity toward HDAC1 or the E98Amutant. 
       Sixteen SAHA analogs functionalized at the hyroxamic group, C-2, C-3, and C-6 with IC50 
values in the micromolar range were ideal candidates for this screen. An initial screen showed 
that most of the SAHA analogs demonstrated equal potencies against both HDAC1 and the 
E98A mutant (Figure 3.13). From the initial screen, C-2-hexyl, C-2-pentyl and N-methyl-SAHA 
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had 5-fold increases in activity for E98A, respectively, compared to the wild type at single 
concentrations (Tables 3.2 and 3.6). We therefore determined the IC50 values for these three 
SAHA analogs. C-2 hexyl and pentyl SAHA had IC50 values of 34.5 µM and 19 µM with E98A 
respectively, compared to IC50s of 170 µM, with the wild type. These results translate to a 5-fold 
increase in selectivity. Similarly, N-methyl SAHA was 5-fold selective for E98A (IC50=2.5 µM) 
over wild type (IC50= 11.5 µM).  These observed 5-fold increases in selectivity are not ideal for a 
bump-hole (The fold-change observed with kinase bump-hole is 100-fold).  
       An alternative to the bump-hole technique is the isolation of HDAC1 selective isoforms. In 
the last year, there has been a tremendous effort in the Pflum lab to develop high throughput 
assays, which would allow for identification of isoform selective inhibitors for all the HDAC 
isoform (unpublished work). Plans are underway to screen small molecules analogs from the 
University of Michigan center. If HDAC1 selective inhibitors are identified, then the selective 
inhibitor will replace the bump-hole strategy and achieve the same goal. This approach can also 
be extended to other inhibitor selective HDAC isoforms resulting from the same screen.  
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3.5: Experimental details 
3.5.1: General equipment 
       Standard biochemical equipment available in the Pflum lab includes centrifuges (Eppendorf 
models 5415D and 5810R), a yeast incubator/shaker (Barnstead labline MaxQMini 4000), a 
Tecan GENios Plus spectrophotometer and a VWR rocking platform.  
3.5.2:  Materials 
       Yeast Nitrogen Base without amino acids, BactoTM Agar, CSM His-Ura and CSM His-Ura-
Trp were purchase from Difco. The rest of lab supplies were generally bought from Sigma 
Aldrich or Fisher Scientific. 
3.5.3: Yeast strains and plasmids 
       The pJK1621 reporter plasmid and the FT5 Δrpd3::HIS3 yeast strain were obtained from 
Dr. Kevin Struhl.[82] The insert from the YEplac112-Rpd3-LexA-FLAG and YEplac112-
Rpd3H150AH151A-LexA-FLAG fusion plasmids were generated from the YEplac112-Rpd3-Lex 
and YEplac112-Rpd3H150AH151A-LexA [82] plasmids via PCR using the following primers: 
Forward primer: CGGGGTACCATGGTATATGAAGCAACACCTTTTGATCCG; reverse primer 
CTGGTTAATTATAAATTAGCCATGGCCTTTATCATCATCATCTTTATAATCCAG 
CCAGTCGCCGTTGCG. The PCR fragments were cloned into Nco1 digested YEp112 Rpd3-
Lex –FLAG plasmid using homologous recombination (Chapter 2, section 2.5.6). Plasmids were 
confirmed by DNA sequencing. 
3.5.4:  Primer details 
       The three-step asymmetric 60 °C-50 °C touchdown PCR method (Chapter 2, section 2.5.3) 
was used to create the insert for a yeast library in the YEplac112-Rpd3LexAFLAG plasmid 
using the following primers:  
KpnRpd3 for: CGGGGTACCATGGTATATGAAGCAACACCTTTTGATCCG 
FLAG+100 rev: CCTAATTCACGTTACCCACC 
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F214X/F215X for: CTTTCCACAAATATGGTGAGNNXNNXCCTGGCACAGGTGAACTG 
F214X/215X rev: CTCACCATATTTGTGGAAAGAAC 
Rpd3L281 (NcoI) for: 
CTCCTTGTCCGGCGATCGTNNXGGTTGCTTTAATCTTTCTATGGAAGGCC 
Where X=G or T 
3.5.5:  Mini-prep of DNA from yeast cells 
       Approximately 100 mm3 cell were obtained from a yeast plate using a sterile Pasteur 
pipette. The cells were dissolved in 1 mL ddH2O and spun at 4200 rpm for 5 minutes. The 
supernatant was removed by aspiration and the cell pellet was resupended in 0.2 mL of 
Triton/SDS solution (10 mM Tris-Cl, pH 8.0, 2% (v/v) Triton X-100, 1% (w/v) SDS, 100 mM and 
1 mM EDTA); the solution was filtered with 0.2 µM filters to sterilize. To the cell mixture, 1:1 
equilibrated phenol: chloroform (0.2 mL) and glass beads (0.3 g) were added. The mixture was 
vortexed for 2 minutes at room temperature and TE buffer (0.2 mL; 10 mM Tris, pH 8.0, 1 mM 
EDTA) was added, followed by spinning at 5 minutes at 13200 rpm. The top aqueous layer was 
transferred to a clean epitube containing 1 mL ethanol, mixed by inversion, and spun for another 
5 minutes at 13200 rpm. The supernatant was removed and the remaining DNA pellet was 
dissolved into 400 µL TE buffer containing 20 µg/mL RNase A. The mixture was incubated for 5 
minutes at room temperature and centrifuged at 13200 rpm for 5 minutes. The aqueous layer 
was transferred into an epitube containing 1 mL ethanol and 80 µL 10 M ammonium acetate. 
This solution was spun at 13200 rpm for 5 minutes and the ethanol was discarded. The DNA 
pellet was dissolved in 20 µL ddH2O for storage at -20 °C. 
3.5.6:   Yeast transformation of plasmid DNA 
       Approximately 10 yeast colonies from a fresh growth plate were transferred into a solution 
containing 333 µL 60% PEG 3350, 50 µL 1 M DTT (dithiothreitol), 50 µL of 2 N lithium acetate, 
and 67 µL water (this mixture is sufficient for 5 transformations). Cells were mixed thoroughly by 
vortexing to disperse the PEG. To this mixture, 10 µL 10 mg/mL salmon sperm DNA and 1 µL 
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0.5 µg/mL plasmid DNA was added. The mixture was incubated on ice for 30 minutes, then at 
45 °C for 45 minutes, and finally transferred to ice for a further 5 minutes.  Aliquots (100 µL) 
were plated on yeast plates with appropriate selection medium (CSM-His-Ura in the case of the 
pJK1521 plasmid; or CSM-His-Trp-Ura, in the case of pJK1561 plus Rpd3 expression plasmids) 
(Difco). Cells were grown at 30 °C for 3-7 days until colonies were observed.  A note about 
making of these yeast plates: Yeast plates were prepared by mixing Yeast Nitrogen Base 
(6.7%), CSM-His-Ura-Trp or CSM-His-Ura (0.77%), dextrose (5%) and 2% BactoAgar in distilled 
water. The mixture was autoclaved and poured into petri dishes and allowed to solidify. Plates 
were used immediately or stored at 4 °C until use. Yeast growth media was prepared in a 
similar manner but without the BactoAgar. 
 3.5.7:  X-Gal agarose overlay assay 
       For X-Gal assay optimization (Section 3.2.1.2 and figure 3.5), a single colony from a yeast 
transformation (section 3.5.8) was re-dissolved in 20 µL distilled water and spotted on wells. To 
make the wells, yeast nitrogen base (6.7%), CSM-His-Ura-Trp or CSM-His-Ura (0.77%), 
dextrose (5%) and 2% BactoAgar were mixed in distilled water, autoclaved, poured into 96-well 
white plates (100 µL per well) using a pipette, and allowed to solidify. After spotting the wells, 
cells were allowed to grow for 2-3 days at 30 °C. To perform the X-Gal overlay assay, low-
melting agarose (5 mg/mL, Life technologies # No. 15517-022) was added to a 10 mL stock 
solution consisting of 0.5 M potassium phosphate buffer, pH 7.0, 6% DMF and 1% SDS. The 
0.5M potassium phosphate buffer pH 7.0 was prepared by mixing 61 mL 1M K2HPO4 , 39 mL 1 
M KH2PO4 and 100mL distilled water, followed by filtering to sterilize. DMF and SDS help to 
permeabilize the cell. The agarose mixture was boiled by microwaving for approximately 1 
minute. To the warm mixture, X-Gal (0.1-0.5 mg/mL), 50 µL β-mercaptoethanol, and 100 µM 
trichostatin A (or 2% DMSO control) were added. Using a Pasteur pipette, the mixture was 
transferred to the surface of the well (200 µL was enough to cover the surface). The agar was 
allowed to cool and solidify and then incubated at 30 °C until blue color was observed (usually 
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4-6 hours). The colonies were retrieved by scraping off the top X-gal agar, and used for the 
ONPG assay (section 3.5.8) 
3.5.8:  Liquid β-galactosidase ONPG assay  
       For ONPG assay optimization (Section 3.2.1.3 and figure 3.6), colonies were retrieved from 
beneath the agar surface of wells (section 3.5.7) using a Pasteur pipette. Colonies were 
separately grown overnight at 30 °C with shaking at 200 rpm in 0.5-1.5 mL yeast media (section 
3.5.6) containing the appropriate amino acid complementation; CSM-His-Ura (for FT5 
Δrpd3::HIS3 expressing pJK1621) or CSM-His-Trp-Ura (for FT5 Δrpd3::HIS3 expressing 
pJK1621 and YEplac112-Rpd3LexAFLAG). The overnight culture was diluted to A600=0.1, 100 
µM trichostatin A added (or 2% DMSO for control), and it was grown to A600=0.4-1.0. Cells were 
collected by spinning at 13200 rpm for 10 minutes at room temperature. The medium was 
removed by aspiration and the cell pellet was resuspended into 0.5 mL of buffer Z, (0.1 M 
Na2HPO4.7H2O, pH 7.0, 0.04 M NaH2PO4, 0.1 M KCl, 2 M MgSO4 and 2.7 µL/mL β-
mercaptoethanol).  SDS (25 µL 0.1%), chloroform (20 µL) and 100 µL of 4 mg/mL 2-Nitrophenyl 
β-D-galactopyranoside (ONPG, from SIGMA) was added to the mixture, followed by vortexing 
for 30 seconds. The mixture was incubated for 1 hour or until yellow color appeared. Na2CO3 
(100 µL 1 M) was added to quench the reaction. Cell debris was removed by spinning at 6000 
rpm for 1 minute and the OD420 measured from a 300 µL sample of the supernatant. Normalized 
units of β-galactosidase activity were calculated using the following equation: Units = (OD420 x 
1000) / (OD600 x T x V), where T= ONPG incubation time in minutes, V= volume used to 
measure absorbance, OD420 in µL and OD600 is the absorbance of diluted overnight culture after 
growth for several hours. The fold change in β-gal activity for each mutant was normalized to 
that of the wild type Rpd3 (Normalized units were set to one).  
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3.5.9: Procedure for screening Rpd3 library 
3.5.9.1 Rpd3 library transformation 
       Plasmid DNA containing Rpd3 mutants was transformed as described in section 3.5.6. 
Briefly, Approximately 10 yeast colonies of FT5 Δrpd3::HIS3 from a fresh growth plate were 
transferred into a solution containing 333 µL 60% PEG 3350, 50 µL of 1 M DTT (dithiothreitol), 
50 µL of 2 N lithium acetate, and 67 µL water (this mixture is sufficient for 5 transformations). 
Cells were mixed thoroughly by vortexing to disperse PEG. To the mixture, 10 µL 10 mg/mL 
salmon sperm DNA and 1 µL 0.5 µg/mL plasmid DNA were added. The mixture was incubated 
on ice for 30 minutes, and then at 45 °C for 45 minutes, and finally transferred to ice for a further 
5 minutes.  Aliquots (100 µL) were plated on yeast plates with amino acid complementation 
CSM-His-Trp-Ura. Cells were grown at 30 °C for 3-7 days until colonies were observed. Yeast 
plates were stored at -4 °C until use.   
3.5.9.2 X-Gal overlay assay for Rpd3 library 
       X-Gal overlay solution was prepared and overlaid on yeast plates from section 3.5.9.1 as 
described in section 3.5.7. Plates were overlaid with X-Gal solution using a Pasteur pipette (10 
mL was enough to cover the surface of the plate). The agar was allowed to cool and solidify and 
then incubated at 30 °C until blue color was observed (usually 4-6 hours). White colonies were 
retrieved from agar by scrapping off the top agarose solid and separately inoculated in 2 mL 
yeast growth medium with amino acid complementation CSM-His-Trp-Ura. 
3.5.9.3: Liquid β-galactosidase ONPG assay for Rpd3 library 
       White colonies identified from section 3.5.9.2 were separately grown in 2 mL yeast growth 
medium with amino acid complementation CSM-His-Trp-Ura overnight at 30 °C with shaking at 
200 rpm. ONPG assay was conducted as described in section 3.5.8. 
3.5.10:  Yeast lysis protocol 
       Yeast cells were grown at 30 ºC overnight in 5 mL CSM-His-Ura (for FT5 Δrpd3::HIS3 
expressing pJK1621) or CSM-His-Trp-Ura (for FT5 Δrpd3::HIS3 expressing pJK1621 and 
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YEplac112-Rpd3LexAFLAG) with shaking. Cells were collected by spinning at 6000 rpm for 5 
minutes. The cell pellet was resuspended in 1 mL yeast lysis buffer F (20 mM HEPES, pH 7.9, 
150 mM NaCl, 10% glycerol) and 3 g glass beads were added. Protease inhibitor cocktail set V 
(1X, Calbiochem) was added and cells were lysed by a successive 6-8 rounds of vortexing at 
maximum settings for 30 seconds, followed by cooling on ice for 45 seconds. After the last 
vortex cycle, cells were incubated on ice for 2 min to allow glass beads to settle. The cell extract 
was transferred to a clean epitube and cell lysates (supernatant) were recovered by spinning at 
6000 rpm for 5 minutes, followed by immediate use or storage at -80 °C until use. 
3.5.11:  Histone deacetylase assay and immunoprecipitation  
       Lysates prepared from the FT5 Δrpd3::HIS3 yeast strain expressing FLAG tagged Rpd3-
LexA fusions were prepared as described in section 3.5.10. Expressed wild-type and mutant 
FLAG-tagged Rpd3 proteins were immunoprecipitated from the lysates (200 µg of extract for 
each immunoprecipitation) by incubating with 15 μL of an anti-FLAG agarose bead slurry 
(Sigma) in buffer F (1 mL 20 mM HEPES, pH 7.6, 1 mM EDTA, 150 mM  NaCl, 20% glycerol) 
for 2 hours at 4 °C with inversion. After 2 hours, beads were recovered by spinning at 4000 rpm 
for 5 minutes at 4 °C. The supernatant was removed and beads washed three times in 1 mL 
buffer F by a successive spinning and supernatant removal process. The beads were split into 
half: one half was used for the HDAC assay, the other half was used for gel analysis (Section 
3.5.11). The deacetylase activity of immunoprecipitated proteins was measured using the Fluor 
de Lys fluorescence activity assay kit (Biomol) as described in chapter 2 (section 2.5.16).  
3.5.12: SDS-PAGE and Western 
       SDS-PAGE was run in s 10% gel as described in chapter 2 (section 2.5.14). The gel was 
transferred to PVDF membranes as described in chapter 2 (section 2.5.15), probed with anti-
LexA antibodies (Promega) and visualized as described in chapter 2 (section 2.5.16). 
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3.5.13:  Plate based ELISA assay 
       Anti-mouse secondary antibody coated plates (G Biosciences) were washed three times 
with 1X TBST wash buffer (0.2 M Tris base, 1.37 M NaCl, 0.2 M KCl and 0.0005% Tween). The 
anti-FLAG antibody (Sigma) was dissolved in 1XTBST containing 3% BSA to a final 
concentration of 10 µg/mL  and 100 µL was added to the plate and was incubated at room 
temperature for 1 hour with rocking (Rocking platform VWR) or overnight at 4 °C. The antibody 
solution was removed by inverting the plate and the plate was washed ten times wish 1XTBST 
wash buffer using a squirt bottle.  Lysates of FLAG-fusion wild type or mutant proteins were 
prepared as described in chapter 2, (section 2.5.13) and were diluted in 1XTBST containing 
10% non-fat dry milk (3 % BSA can also be used) to a final concentration of 10 µg/mL. An 
aliquot (100 µL) was added to the plate and incubated for 1 hour with rocking at 4 °C. The 
lysates were removed by inversion and washed ten times in 1XTBST using a squirt bottle.  
GloTM substrate (25µL; Promega) was added and incubated for 25 minutes without shaking at 
room temperature, after which the luminescence was determined using the Genios plate reader 
(Tecan). The luminescence signal for each mutant was normalized to the wild type (set at 
100%) and standard error from at least four independent trials are shown in the appendix B.4. 
3.5.14: Screening SAHA analogs using 96-well plate ELISA assay 
       The screen was done as described in section 3.5.10 with some modifications. After removal 
of the lysates and washing, the small molecule was dissolved in DMSO (see appendix B Tables, 
B.5-B.10 and Tables 3.2, 3.4 and 3.6 for concentrations) and incubated for 15 minutes. The 
DMSO concentration was kept at a constant 2% for all reactions. Then, 25 µL of the GloTM 
substrate (Promega) was added and left for 25 minutes without shaking, after which the 
luminescence was determined using the Genios plate reader. Several controls were included; a 
DMSO control (2%) for both the wild type and mutant protein and a no protein control with 2% 
DMSO for background luminescence. The normalized deacetylase activity was determined by 
subtracting the amount of luminescence from the no protein control with 2% DMSO. The 
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percent activity at each small molecule concentration was calculated by determining the percent 
luminescence activity in the presence of inhibitor versus absence of inhibitor. 
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APPENDIX A. 
Table A.3: Percent deacetylase activities for HDAC1 alanine mutants. 
Protein Trial1 Trial 2 Trial 3 Trial 4 Trial 5 Trial 6 Mean S.E 
No protein  6   25  22   13 ND ND   16 4.0 
Wild-Type 100   100  100   100   100 ND   100 0.0 
H141A  18   20   25   15   20 ND   19 1.5 
V19A  44   31   25   37   17    ND   31 4.5 
Y23A  30   69   31   25   36  18   35 7.0 
Y24A  23    49   20   35   20   8   26 6.0 
M30A   20   5   36   18  ND  ND   20 6.0 
R34A   42     41   13   17   42 ND   31 6.5 
I35A   5   4   3   14   3  ND   5.8 2.0 
R36A   38   26   16   26   20  ND   25 4.0 
S113A   71   70   51   66   51  ND   62 4.0 
L139A  40   39   37   41  ND ND   39 1.0 
C151A   11   21   39   11   30   15   21 4.5 
Y303A   10   6    7   9    2   ND   6.7 1.5 
 
HDAC1 wild-type or alanine mutants were expressed as FLAG-tagged fusion proteins and were 
immunoprecipitated with anti-FLAG-agarose bead resin. The immunoprecipitated proteins were 
tested for deacetylase activity using an in vitro fluorescence assay, as described in section 
2.5.16. The mean percent activity for each independent trial compared to that of the wild-type 
protein (100%) with standard error (S.E) is shown. ND = Not determined (Data shown in Figures 
2.9 and 2.11 in text). 
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Table 4: Percent deacetylase activities for HDAC1 rescue mutants 
Protein Trila1 Trial 2 Trial 3 Trial 4 Trial 5 Trial 6 Mean S.E 
No protein 18  11 2.7 3.0 1.9 ND 7.4 3.1 
Wild-Type 100 100 100 100 100 ND 100 0.0 
Y23F 5 7 13 25 10 ND 12 3.5 
Y24F 57 31 81 44 69 ND 56 9.0 
R34K 17 16 14 18 7 28 17 3.0 
R36K 29 41 30   ND ND ND 33 3.5 
C151S 33 25 29 30 31 ND 30 1.0 
Y303F 50 33 37 31 ND ND 38 4.0 
 
HDAC1 wild-type or alanine mutants were expressed as FLAG-tagged fusion proteins and were 
immunoprecipitated with anti-FLAG-agarose bead resin. The immunoprecipitated proteins were 
tested for deacetylase activity by an in vitro fluorescence assay, as described in section 2.5.16. 
The mean percent activity for each independent trial compared with that of the wild-type protein 
(100%) with standard error (S.E) is shown. ND = Not determined (Data shown in figure 2.12 in 
text). 
. 
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Table 5: Percentage remaining HDAC activity after incubation of acetate with HDAC1 
Concentration (M) Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 Mean S.E 
2.5 x 10-2 10 22 15 23 21 18 2.4 
1.25 x 10-2 36 31 31 24 31 31 2 
6.25 x 10-3 55 55 44 61 50 53 2.8 
3.125 x 10-3 63 83 81 74 ND 75 4.5 
1.56 x 10-3 80 107 98 98 ND 96 5.6 
 
Deacetylase activity of wild type was determined at each sodium acetate concentration using an 
in vitro fluorescence assay as described in section 2.5.16. The percentage deacetylase activity 
of each independent trial, mean percentage deacetylase activity, and standard error (S.E) at 
each acetate concentration are shown. ND = Not determined. 
 
 
 
 
 
 
 
 
 
 
 
92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40: IC50 Curve of Acetate with wild type HDAC1. A plot showing the percentage 
deacetylase activity of wild type HDAC1 versus acetate concentration. Data was fit to a 
sigmoidal curve using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The inset is 
the results of the data analysis and the calculated IC50 (m3 in molar) is given with error. 
Graph included in Figure 2.13, Figure 2.14, and Table 1.1. 
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Table 6: Percentage remaining HDAC activity after incubation of acetate with 
HDAC1R34A 
Concentration (M) Trial 1 Trial 2 Trial 3 Trail 4 Trial 5 Mean S.E 
2.0 x 10-1  7.8 12 20 20 8  14 3 
6.6 x 10-2 33 26 25 24 21 26 4.5 
2.25 x 10-2 50 40 64 42 38 47 8.7 
7.4 x 10-3 73 72 70 65 81 73 12 
2.46 x 10-3 96 82 82 82 116 92 16 
Deacetylase activity of HDAC1R34A mutant was determined at each sodium acetate 
concentration using an in vitro fluorescence assay, as described in section 2.5.16.The 
percentage deacetylase activity of each independent trial, mean percentage deacetylase activity 
and standard error (S.E) at each acetate concentration are shown.  
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Figure 41: IC50 Curve of Acetate with HDAC1R34A. A plot showing the percentage deacetylase 
activity of HDAC1R34A versus acetate concentration. Data was fit to a sigmoidal curve using 
Kaleidograph 4.0 (Synergy Software) to determine the IC50. The inset is the results of the data 
analysis and the calculated IC50 (m3 in molar) is given with error. Graph included in Figure 2.13 and 
Table 1.1. 
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Table 7: Percentage remaining HDAC activity after incubation of acetate with 
HDAC1Y23A. 
Concentration (M) Trial 1 Trial 2 Trial 3 Trial 4 Mean S.E 
2.0 x 10-1 7.5 23 20 13 16 3 
6.6 x 10-2 17 40 25 25 27 4.5 
2.25 x 10-2 44 50 64 55 53 8.7 
7.4 x 10-3 75 55 70 71 68 12 
2.46 x 10-3 84 89 82 90 86 16 
Deacetylase activity of HDAC1Y23A mutant was determined at each sodium acetate 
concentration using an in vitro fluorescence assay, as described in section 2.5.16. The 
percentage deacetylase activity of each independent trial, mean percentage deacetylase activity 
and standard error (S.E) at each acetate concentration are shown.  
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Figure 42: IC50 Curve of Acetate with HDAC1Y24A: A plot showing the percentage 
deacetylase activity of HDAC1R34A versus acetate concentration. Data was fit to a 
sigmoidal curve using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The 
inset is the results of the data analysis and the calculated IC50 (m3 in molar) is given 
with error. Graph included in Figure 2.14 and Table 1.1. 
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Table 8: Percentage remaining HDAC activity after incubation of acetate with 
HDAC1Y24A. 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
2.0 x 10-1 13 23 8 15 4.4 
6.6 x 10-2 25 32 17 24 4.3 
2.25 x 10-2 55 46 44 48 3.3 
7.4 x 10-3 71 60 75 69 4.4 
2.46 x 10-3 80 83 84 82 1.2 
 
Deacetylase activity of HDAC1Y24A mutant was determined at each sodium acetate 
concentration using an in vitro fluorescence assay, as described in section 2.5.16. The 
percentage deacetylase activity of each independent trial, mean percentage deacetylase activity 
and standard error (S.E) at each acetate concentration are shown.  
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Figure 43: IC50 Curve of Acetate with HDAC1Y24A. A plot showing the percentage 
deacetylase activity of HDAC1Y24A versus acetate concentration. Data was fit to a sigmoidal 
curve using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The inset is the results 
of the data analysis and the calculated IC50 (m3 in molar) is given with error. Graph included in 
Figure 2.14 and Table 1.1. 
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Table A.9: Percentage remaining HDAC activity after incubation of acetate with 
HDAC1R36A. 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
2.0 x 10-1 16 24 16 19 2.6 
6.6 x 10-2 37 21 37 32 5.3 
2.25 x 10-2 46 39 46 44 2.3 
7.4 x 10-3 60 55 60 58 1.6 
2.46 x 10-3 77 72 77 75 1.6 
 
Deacetylase activity of HDAC1R36A mutant was determined at each sodium acetate 
concentration using an in vitro fluorescence assay, as described in section 2.5.16. The 
percentage deacetylase activity of each independent trial, mean percentage deacetylase activity 
and standard error (S.E) at each acetate concentration are shown.  
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Figure 44: IC50 Curve of Acetate with HDAC1R36A. A plot showing the percentage deacetylase 
activity of HDAC1R36A versus acetate concentration. Data was fit to a sigmoidal curve using 
Kaleidograph 4.0 (Synergy Software) to determine the IC50. The inset is the results of the data 
analysis and the calculated IC50 (m3 in molar) is given with error. Graph included in Figure 2.13 and 
Table 1.1. 
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Table A.10: Percentage remaining HDAC activity after incubation of acetate with 
HDAC1C151A. 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
2.0 x 10-1 10 23 10 14 4.3 
6.6 x 10-2 20 33 20 24 4.3 
2.25 x 10-2 38 39 38 38 0.3 
7.4 x 10-3 58 62 58 59 1.3 
2.46 x 10-3 72 86 84 81 4.3 
 
Deacetylase activity of HDAC1C151A mutant was determined at each sodium acetate 
concentration using an in vitro fluorescence assay, as described in section 2.5.16. The 
percentage deacetylase activity of each independent trial, mean percentage deacetylase activity 
and standard error (S.E) at each acetate concentration are shown.  
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Figure 45: IC50 Curve of Acetate with HDAC1C151A. A plot showing the percentage 
deacetylase activity of HDAC1C151A versus acetate concentration. Data was fit to a 
sigmoidal curve using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The 
inset is the results of the data analysis and the calculated IC50 (m3 in molar) is given with 
error. Graph included in Figure 2.14 and Table 1.1. 
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Table A.11: Percentage remaining HDAC activity after incubation of acetate with 
HDAC1F205Y. 
Concentration (M) Trial 1 Trial 2 Trial 3 Trail 4 Mean S.E 
2.5 x 10-2 19 26 21 26 23 1.7 
1.25 x 10-2 35 33 33 ND 34 0.6 
6.25 x 10-3 50 47 47 60 51 3.1 
3.125 x 10-3 65 88 88 73 79 5.0 
1.56 x 10-3 102 99 99 97 99 1.2 
 
Deacetylase activity of HDAC1F205Y mutant was determined at each sodium acetate 
concentration using an in vitro fluorescence assay as described in section 2.5.16. The 
percentage deacetylase activity of each independent trial, mean percentage deacetylase activity 
and standard error (S.E) at each acetate concentration are shown. ND = Not determined. 
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Figure 46: IC50 Curve of Acetate with HDAC1F205Y. A plot showing the percentage 
deacetylase activity of HDAC1F205Y versus acetate concentration. Data was fit to a sigmoidal 
curve using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The inset is the results 
of the data analysis and the calculated IC50 (m3 in molar) is given with error. Graph included in 
Figure 2.13 and Table 1.1. 
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APPENDIX B. 
 
Table B.12: Quantitative inhibition of Rpd3 activity (data obtained by Sujith Weerasighe) 
Sample 
 
Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 Mean  S.E 
LACZ reporter 
 
3.49 2.92 3.40 6.49 5.95 4.45 0.73 
LACZ reporter + 
TSA 100µM 
2.87 2.78 4.59 4.81 6.21 4.25 0.65 
Wt Rpd3 
 
1.00 1.00 1.00 1.00 1.00 1.00 - 
Wt Rpd3 + 
TSA 100µM 
1.42 1.47 2.16 1.58 1.44 1.61 0.12 
Rpd3 mutant 
 
2.32 2.02 2.90 3.30 4.25 2.96 0.39 
Rpd3 mutant + 
TSA 100µM 
2.21 2.50 3.20 4.81 5.2 3.58 0.61 
 
LACZ reporter plasmid, pJK1621, was transformed with or without wild type Rpd3 or 
catalytically inactive Rpd3 mutant as LexA-FLAG fusions into FT5 Δrpd3::HIS yeast strain. 
Transformed cell were grown with or without TSA for 6h at 30°C and β-galactosidase activity 
was measured quantitatively using ONPG as the substrate.  Relative fold changes in β-
galactosidase activity was calculated with respect to wild type Rpd3 as described and mean fold 
change observed with three independent trial is shown with standard error (S.E). ND= Not 
determined. Data shown in figure 3.6 in the text. 
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Table 13: A representative quantitative ONPG inhibition of Rpd3 mutant(s) activity. 
 
 
LACZ reporter plasmid, PJK1621, was transformed with or without wild type Rpd3 (or 
catalytically inactive Rpd3) or plasmid DNA from Rpd3 library mutant as LexA-FLAG fusions into 
FT5 Δrpd3::HIS yeast strain. Transformed cells were grown for 6h at 30°C and β-galactosidase 
activity was measured quantitatively using ONPG as the substrate.  Relative fold changes in β-
galactosidase activity was calculated with respect to wild type Rpd3 as described and data from 
2 trials is shown. Data shown in Figure 3.8 of the text. 
 
 
Table 14: Deacetylase activity of immunoprecipitated wild type or Rpd3 mutants 
 Wild type RpdH150A 
H151A 
3 4 5 6 10 
Trial 1 100 16 86 33 26 79 21 
Trial 2 100 25 99 40 20 80 30 
 
Lysates were prepared from FT5 Δrpd3::HIS3 yeast strain expressing FLAG tagged Rpd3-LexA 
fusion proteins and immunoprecipitated as described in section 3.8. The deacetylase activity of 
immunoprecipitated proteins was measured using Fluor de Lys fluorescence activity assay kit. 
Percentage deacetylase activity for two trials is shown. Data shown in Figure 3.9 of the text. 
 
 
 
 
 WildType Rpd3H150A 
H151A 
1 2 3 4 5 6 7 8 9 10 
Trial 
1 
1.0 4.4 4.1 4.0 1.2 2.7 3.7 7.1 6.3 3.3 4.4 1.4 
Trial 
2 
1.0 4.7 3.5 4.5 1.5 2.5 3.9 6.5 6.5 3.5 4.7 1.2 
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Table 15: Validation of plate based ELISA assay  
 
 
Deacetylase activity was determined using ELISA assay as described (Chapter 3, section 
3.5.14). Percentage deacetylase activity of each independent trial, mean percentage 
deacetylase activity and standard error (S.E) are shown. Data shown in Figure 3.12 of the text. 
 
 
 
 
 
 
Table 16: Percentage remaining HDAC activity after incubation of SAHA C-2-hexyl with 
HDAC1 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
4.8 x 10-2 35 21 31 30 4.1 
2.4 x 10-2 57 39 23 40 9.8 
1.2 x 10-2 63 52 66 60 4.2 
6.0 x 103 72 64 73 70 2.8 
3.0 x 10-3 75 90 96 87 6.2 
 
Deacetylase activity was determined at each SAHA C-2-hexyl concentration using ELISA assay 
as described (Chapter 3, section 3.5.14). Percentage deacetylase activity of each independent 
trial, mean percentage deacetylase activity and standard error (S.E) at each concentration are 
shown. Data shown in Figure 3.13 of the text. 
 
 
Protein Trial 1 Trial 2 Trial 3 Trial 4 Mean S.E 
No protein 24 10 21 21 19 3.0 
H141A 10 15 10 8 10 1.4 
HDAC1 100 100 100 100 100 - 
E98A 110 119 120 114 115 2.3 
HDAC1 + TSA  25 20 25 19 22 1.6 
E98A + TSA  25 30 24 34 28 2.3 
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Table 17: Percentage remaining HDAC activity after incubation of SAHA C-2-hexyl with 
HDAC1E98A 
 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
1.2 x 10-2 32 14 6 17 7.6 
6.0 x 10-3 43 40 14 32 9.2 
3.0 x 10-3 73 47 46 55 8.8 
1.5 x 10-3 73 67 60 67 3.7 
7.5 x 10-4 91 80 94 88 4.2 
 
Deacetylase activity was determined at each SAHA C-2-hexyl concentration using ELISA assay 
as described (Chapter 3, section 3.5.14). Percentage deacetylase activity of each independent 
trial, mean percentage deacetylase activity and standard error (S.E) at each concentration are 
shown.  Data shown in Figure 3.13 of the text. 
 
Table 18: Percentage remaining HDAC activity after incubation of SAHA C-2-pentyl with 
HDAC1 
 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
2.4 x 10-2 24 29 35 30 3.1 
1.2 x 10-2 38 44 46 43 2.4 
6.0 x 10-3 65 68 57 63 3.2 
3.0 x 10-3 97 71 68 78 9.2 
1.5 x 10-3 94 94 94 94 - 
 
Deacetylase activity was determined at each SAHA C-2-pentyl concentration using ELISA 
assay as described (Chapter 3, section 3.5.14). Percentage deacetylase activity of each 
independent trial, mean percentage deacetylase activity and standard error (S.E) at each 
concentration are shown. Data shown in Figure 3.14 of the text. 
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Table 19: Percentage remaining HDAC activity after incubation of SAHA C-2-pentyl with 
HDAC1E98A 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
6.0 x 10-3 15 33 22 23 5.2 
3.0 x 10-3 23 51 34 36 8.1 
1.5 x 10-3 66 62 48 58 5.4 
7.5 x 10-4 77 83 54 71 8.8 
3.75 x 10-4 88 95 74 85 6.1 
 
Deacetylase was determined at each SAHA C-2-pentyl concentration using ELISA assay as 
described (Chapter 3, section 3.5.14). Percentage deacetylase activity of each independent 
trial, mean percentage deacetylase activity and standard error (S.E) at each concentration are 
shown.  Data shown in Figure 3.14 of the text. 
 
 
 
Table 20: Percentage remaining HDAC activity after incubation of N-methyl SAHA with 
HDAC1 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
2.56 x 10-3 18 40 20 26 7.0 
1.28 x 10-3 52 44 68 54 7.0 
6.4 x 10-4 65 51 54 56 4.2 
3.2 x 10-4 79 79 99 85 6.6 
1.6 x 10-4 113 87 86 95 8.8 
 
Deacetylase activity was determined at each N-methyl SAHA concentration using ELISA  assay 
as described (Chapter 3, section 3.5.14). Percentage deacetylase activity of each independent 
trial, mean percentage deacetylase activity and standard error (S.E) at each concentration are 
shown. Data shown in Figure 3.15 of the text. 
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Table 21: Percentage remaining HDAC activity after incubation of N-methyl SAHA with 
HDAC1E98A 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
6.4 x 10-4 38 35 8 27 9.5 
3.2 x 10-4 62 44 29 57 9.5 
1.6 x 10-4 81 54 39 58 12 
8.0 x 10-5 83 70 78 77 3.7 
4.0 x 10-5 98 85 84 90 4.5 
 
Deacetylase was determined at each N-methyl SAHA concentration using ELISA assay as 
described in Chapter 3, section 3.5.14. Percentage deacetylase activity of each independent 
trial, mean percentage deacetylase activity and standard error (S.E) at each concentration are 
shown. Data shown in Figure 3.15 in text. 
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Figure 47: Structures of SAHA C2 analogs 
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Figure 48: Structures of SAHA C3 analogs 
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     Histone deacetylase 1 (HDAC1) has been linked to cell growth and cell cycle regulation, 
which makes it a widely recognized target for anticancer drugs. The 14 Å channel of Class 1 
HDAC isotypes has long being hypothesized to be the exit cavity for acetate following 
deacetylation. The amino acids lining this cavity are very similar among the HDAC isoforms, 
suggesting the role of the cavity is relevant to all HDACs proteins Importantly, HDAC1 selective 
inhibitors designed to fit the 14Å channel have been designed. To understand the importance of 
the 14Å channel to HDAC1 activity, we used an alanine scan to determine the influence of 
residues in the 14 Å channel of the HDAC1. The mutation of eleven channel residues to alanine 
led to a significant reduction in deacetylase activity. Acetate competition experiment revealed 
that, charged residues lining the 14Å affect HDAC1 binding to acetate. The combined results 
reveal 14Å channel residues critical for HDAC1 activity and acetate escape. With no 
crystallographic information on HDAC1 available, these findings provide important insight HDAC 
inhibitor design.  
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         Understanding the involvement of HDAC1 in cancer formation is critical in developing 
selective inhibitors. Towards this goal, we did extensive studies to create a HDAC1 bump-hole 
inhibitors pair as an alternative to genetic methods which are limited in their usage to 
characterize HDAC1 function. We developed and validated a histone deacetylase dependent 
screen in the yeast Rpd3 protein. Using this screen screened a library of Rpd3 mutants with the 
aim of isolating active mutants for the bump-hole. Of the 15, 000 colonies screened none had a 
mutation. We focused on testing the active E98A mutant against SAHA inhibitor analogs 
present in our lab. C-2, C-3 and N-SAHA analogs were screened using a plate based ELISA 
assay which we developed and validated.  All SAHA analogs screened did not qualify for a 
HDAC1-bump inhibitor system.  
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